UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q/A
(Amendment No. 1)
 
 
[X]
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the quarterly period ended March 31, 2019
 
 
[   ]
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Commission file number: 001-38116
 
YOUNGEVITY INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
Delaware
 
90-0890517
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
 
 
 
2400 Boswell Road, Chula Vista, CA
 
91914
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrant’s Telephone Number, Including Area Code:  (619) 934-3980
 
           Not applicable         
Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report
 
Securities registered pursuant to Section 12(b) of the Act: None
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
 
 
 
 
Securities registered pursuant to Section 12(g) of the Act:
 
Common Stock, $0.001 par value
9.75% Series D Cumulative Redeemable Perpetual Preferred Stock, $0.001 par value
 
 
Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes [  ] No [X]
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Sec.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes []  No [X]
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
[ ]
Accelerated filer
[ ]
Non-accelerated filer
[X]
Smaller reporting company
[X]
 
 
Emerging growth company
[ ]
 
 
 
 
If an emerging growth company indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [ ] 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes [ ]  No [X]
 
As of May 16, 2019, the issuer had 28,890,671 shares of its Common Stock, par value $0.001 per share, issued and outstanding.


 
 
 
EXPLANATORY NOTE
 
 
 
On October 13, 2020, the Audit Committee of the Board of Directors (the “Board”) of Youngevity International, Inc., (together with its subsidiaries, the “Company”, “we”, “our” or “us”), following discussion with management, determined that the unaudited condensed consolidated financial statements (the “Previously Issued Financial Statements”) presented in the Company’s Quarterly Report for the quarterly periods ended March 31, 2019, June 30, 2019 and September 30, 2019 filed with the Securities and Exchange Commission (the “SEC”) should no longer be relied upon as a result of the following error:
 
       During the three months ended March 31, 2019 certain revenues related to green coffee sales, within the Company’s commercial coffee segment, that were recognized at gross should have been recorded at net.
 
During the Company’s 2019 annual audit, it was determined that the Company had not fairly valued certain assets acquired in its acquisition of Khrysos Global, Inc., as of the closing date. As a result, the Company is restating its financial statements related to its commercial hemp segment detailed below for the following error:
 
During the three months ended March 31, 2019, the fair value of certain fixed assets acquired in the acquisition of Khrysos Global, Inc., and the share price valuation for the common stock issued as consideration for the acquisition were not fairly valued as of the closing date.
 
A description of the restatement is presented in Note 2 under the caption Restatement of previously reported unaudited condensed consolidated financial statements.
 
Accordingly, the Company is filing this Amendment No. 1 (this “Form 10–Q/A”) to amend our Quarterly Report on Form 10–Q for the quarterly period ended March 31, 2019, originally filed with the Securities and Exchange Commission (the “SEC”) on May 20, 2019 (the “Original Filing”), to reflect the amendment and restatement of our Unaudited Condensed Consolidated Balance Sheet at March 31, 2019, Unaudited Condensed Consolidated Statement of Operations for the three months ended March 31, 2019, Unaudited Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2019 and the related notes thereto and related disclosures as of March 31, 2019.  This Form 10–Q/A also amends certain other items in the Original Filing, as listed in “Items Amended in This Filing” below.
 
As required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by the Company’s principal executive officer and principal financial officer are filed as exhibits 31.1, 31.2, 32.1 and 32.2 to this Form 10-Q/A.
 
Background and Effects of the Restatement
 
On October 16, 2020, the Company filed a Current Report on Form 8-K under Item 4.02 with the Securities and Exchange Commission relating to Previously Issued Financial Statements as described below. As indicated in the Current Report on Form 8-K under Item 4.02, the Company determined that a restatement was necessary due to a change in the accounting treatment of its revenue derived from its green coffee sales, which had been accounted for on a gross basis and is now being accounted for on a net basis reflecting the deduction of cost of revenue related to such revenue. During the Company’s 2019 annual audit, the Company reassessed its accounting for revenue derived from its CLR Roasters LLC., (“CLR”) commercial coffee segment, specifically the 2019 green coffee sales program, for sales made by the Company to its joint venture partner, H&H Coffee Group Export Corp. (“H&H Export”), which was the provider of the “wet” green coffee and the buyer of the processed coffee for the three months ended March 31, 2019.
 
Based on its assessment, management has determined that for green coffee sales made by CLR to its joint venture partner, H&H Export, for sales originally recorded at gross (revenue recorded without reduction for cost to purchase the inventory) should have recorded these sales at net. See Note 1, to the condensed consolidated financial statements under “Other Relationship Transactions” for further discussion related to H&H Export.
 
 
-i-
 
 
On February 15, 2019, the Company and Khrysos Industries, Inc., closed its acquisition of Khrysos Global, Inc., detailed further in Note 5 to the unaudited condensed consolidated financial statements below. In conjunction with the Company’s 2019 annual audit the Company concluded that certain fixed assets acquired in the acquisition and the share price valuation for the common stock issued as consideration were not fairly valued as of the closing date including; i) $1,127,000 related to the certain fixed assets, and ii) $1,351,000 related to a change in the fair value of common stock issuance resulting in an increase to goodwill of $2,478,000 acquired and an adjusted aggregate purchase price of $15,894,000.  In addition, this Form 10-Q/A has added to Note 12, to the accompanying notes to the condensed consolidated financial statements disclosure that includes the disclosure of capital expenditures recorded as the result of the acquisition of Khrysos Global Inc., reflecting the change in the fair value of the fixed assets from approximately $2,260,000 to $1,133,000.
 
Accordingly, this Form 10–Q/A restates the Company’s unaudited condensed consolidated financial statements; i) Unaudited Condensed Consolidated Balance Sheet at March 31, 2019, ii) Unaudited Condensed Consolidated Statement of Operations for the three months ended March 31, 2019, iii) Unaudited Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2019, and iv) the Unaudited Condensed Consolidated Statement of Stockholders’ Equity for the three months ended March 31, 2019.
  
For a description of the effect of the restatement as of March 31, 2019 and for the three months ended March 31, 2019, see “Note 2. Restatement of Previously Reported Unaudited Condensed Consolidated Financial Statements” to the Company’s unaudited condensed consolidated financial statements in “Item 1. Financial Statements” contained herein.  In connection with the restatement of the Company’s condensed consolidated financial statements in this Form 10–Q/A, management determined that material weaknesses exist in the Company’s internal control over financial reporting and that the Company’s disclosure controls and procedures were ineffective during this reporting period. For a description of the material weaknesses identified by management and managements implemented and planned remediations for those material weaknesses, please see “Item 4. Controls and Procedures” contained herein.
 
Items Amended in This Filing
 
This Form 10–Q/A sets forth the Original Filing, in its entirety, as amended to reflect the restatement. No attempt has been made in this Form 10–Q/A to modify or update other disclosures presented in the Original Filing to reflect events occurring after the original filing date, except as required to reflect the effects of the restatement.
 
This Form 10–Q/A should be read in conjunction with our filings made with the SEC subsequent to the filing of the Original Filing.
 
The following items have been amended as a result of this restatement:
 
Part I
 
Item 1. Financial Statements;
 
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations;
 
Item 4. Controls and Procedures;
 
Our Principal Executive Officer and Principal Financial Officer are providing currently dated certifications in connection with this Form 10–Q/A.  These certifications are filed as Exhibits 31.1, 31.2, 32.1 and 32.2.  
 
Part II
 
Item 1A. Risk Factors;
Item 6. Exhibits
 
 
 
 
-ii-
 
 
YOUNGEVITY INTERNATIONAL, INC.
TABLE OF CONTENTS
 
 
 
Page
 
 
PART I. FINANCIAL INFORMATION
 
 
  
 
Item 1.
Financial Statements
1
 
Condensed Consolidated Balance Sheets as of March 31, 2019 (unaudited) & December 31, 2018
1
 
Condensed Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018 (unaudited)
2
 
Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2019 and 2018 (unaudited)
3
 
Condensed Consolidated Statements of Stockholders' Equity – Three months ended March 31, 2019 and 2018 (unaudited)
4
 
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018 (unaudited)
6
 
Notes to Condensed Consolidated Financial Statements (unaudited)
7
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
44
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
54
Item 4.
Controls and Procedures
54
 
 

 
PART II. OTHER INFORMATION

 
  

Item 1.
Legal Proceedings
56
Item 1A.
Risk Factors
56
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
57
Item 3.
Defaults Upon Senior Securities
57
Item 4.
Mine Safety Disclosures
57
Item 5.
Other Information
57
Item 6.
Exhibits
58
Signatures
 
59
 
 
 
 
 
-iii-
 
 
PART I. FINANCIAL INFORMATION
 
ITEM 1. FINANCIAL STATEMENTS
 
Youngevity International, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
 
 
 
As of
 
 
 
March 31,
2019
 
 
December 31,
2018
 
ASSETS
 
(Unaudited) (Restated)*
 
 
 
 
Current Assets
 
 
 
 
 
 
       Cash and cash equivalents
 $2,540 
 $2,879 
       Accounts receivable trade (Note 1)
  7,706 
  4,028 
       Income tax receivable
  75 
  74 
       Inventory
  24,164 
  21,776 
       Advances (Note 1)
  - 
  5,000 
       Notes receivable
  5,000 
  - 
       Prepaid expenses and other current assets
  4,891 
  5,263 
Total current assets
  44,376 
  39,020 
 
    
    
Property and equipment, net
  19,729 
  15,105 
Operating lease right-of-use assets
  5,509 
  - 
Deferred tax assets
  148 
  148 
Intangible assets, net
  23,919 
  15,377 
Goodwill
  13,154 
  6,323 
Other assets – notes receivable
  949 
  - 
Total assets
 107,784 
 $75,973 
 
    
    
LIABILITIES AND STOCKHOLDERS' EQUITY
    
    
 
    
    
Current Liabilities
    
    
Accounts payable
 8,861 
 $8,478 
Accrued distributor compensation
  4,143 
  3,289 
Accrued expenses
  6,462 
  6,582 
Deferred revenues
  2,268 
  2,312 
Line of credit
  2,432 
  2,256 
Other current liabilities
  535 
  1,912 
Operating lease liabilities, current portion
  745 
  - 
Finance lease liabilities, current portion
  978 
  1,168 
Notes payable, current portion
  158 
  141 
Convertible notes payable, current portion
  681 
  647 
Warrant derivative liability
  5,369 
  9,216 
Contingent acquisition debt, current portion
  792 
  795 
Total current liabilities
  33,424 
  36,796 
 
    
    
Operating lease liabilities, net of current portion
  4,764 
  - 
Finance lease liabilities, net of current portion
  927 
  1,107 
Notes payable, net of current portion
  10,378 
  7,629 
Convertible notes payable, net of current portion
  1,981 
  - 
Contingent acquisition debt, net of current portion
  7,341 
  7,466 
Total liabilities
  58,815 
  52,998 
 
    
    
Commitments and contingencies (Note 1)
    
    
 
    
    
Stockholders’ Equity
    
    
Preferred Stock, $0.001 par value: 5,000,000 shares authorized
    
    
    Convertible Preferred Stock, Series A - 161,135 shares issued and outstanding at March 31, 2019 and December 31, 2018
  - 
  - 
    Convertible Preferred Stock, Series B – 129,437 shares issued and outstanding at March 31, 2019 and December 31, 2018
  - 
  - 
Common Stock, $0.001 par value: 50,000,000 shares authorized; 28,890,671 and 25,760,708 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively
  29 
  26 
Additional paid-in capital
  244,906 
  206,757 
Accumulated deficit
  (196,023)
  (183,763)
Accumulated other comprehensive income (loss)
  57 
  (45)
    Total stockholders’ equity
  48,969 
  22,975 
 Total Liabilities and Stockholders’ Equity
 107,784 
 $75,973 
 
* The Unaudited Condensed Consolidated Balance Sheet as of March 31, 2019 has been restated. See Note 2.
   
See accompanying notes to condensed consolidated financial statements. 
 
 
-1-
 
 
Youngevity International, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
 
 
 
Three Months Ended
March 31,
 
 
 
2019
(Unaudited)
 
 
2018
 
 
 
  (Restated)*
 
 
 
 
Revenues
 $41,192 
 $42,994 
Cost of revenues
  14,343 
  17,982 
Gross profit
  26,849 
  25,012 
Operating expenses
    
    
Distributor compensation
  14,890 
  15,578 
Sales and marketing
  4,019 
  3,499 
General and administrative
  19,881 
  5,911 
Total operating expenses
  38,790 
  24,988 
Income (loss) from Operations
  (11,941)
  24 
Interest expense, net
  (1,507)
  (1,712)
Change in fair value of warrant derivative liability
  1,486 
  712 
Extinguishment loss on debt
  - 
  (1,082)
Total other expense
  (21)
  (2,082)
Net loss before income taxes
  (11,962)
  (2,058)
Income tax provision
  298 
  250 
Net Loss
  (12,260)
  (2,308)
Preferred stock dividends
  (14)
  (3)
Net Loss Available to Common Stockholders
 $(12,274)
 $(2,311)
 
    
    
Net loss per share, basic
 $(0.45)
 $(0.12)
Net loss per share, diluted
 $(0.49)
 $(0.13)
 
    
    
Weighted average shares outstanding, basic
  27,577,576 
  19,744,144 
Weighted average shares outstanding, diluted
  28,025,172 
  19,758,402 
 
* The Unaudited Condensed Consolidated Statement of Operations for the three months ended March 31, 2019 has been restated. See Note 2.
  
See accompanying notes to condensed consolidated financial statements.
  
 
-2-
 
 
Youngevity International, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Comprehensive Loss
(In thousands)
 
 
 
Three Months Ended
March 31,
 
 
 
2019
 
 
 
2018
 
 
 
 
 
 
 
 
Net loss
 $(12,260)
 $(2,308)
Foreign currency translation
  102 
  201 
Total other comprehensive income
  102 
  201 
Comprehensive loss
 $(12,158)
 $(2,107)
 
See accompanying notes to condensed consolidated financial statements. 
  
 
-3-
 
 
 Youngevity International, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Stockholders' Equity
(In thousands, except shares)
 
 
 
 
Series A
Preferred Stock
 
 
 
Series B
Preferred Stock
 
 
 
Common Stock
 
 
 
Additional
Paid-in Capital
 
 
Accumulated
Other
Comprehensive
 
 
 
Accumulated
 
 
 
Total
Stockholders' Equity
 
 
 
Shares
 
 
Amount
 
 
Shares
 
 
Amount
 
 
Shares
 
 
Amount
 
 
(Restated)*
 
 
Loss
 
 
Deficit
 
 
(Restated)*
 
Balance at December 31, 2018
  161,135 
 $- 
  129,437 
 $- 
  25,760,708 
 $26 
 $206,757 
 $(45)
 $(183,763)
 $22,975 
Net loss
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  (12,260)
  (12,260)
Foreign currency translation adjustment
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  102 
  - 
  102 
Issuance of common stock from at-the-market offering and exercise of stock options and warrants, net
  - 
  - 
  - 
  - 
  309,636 
  1 
  1,454 
  - 
  - 
  1,455 
Issuance of common stock for services
  - 
  - 
  - 
  - 
  75,000 
  - 
  417 
  - 
  - 
  417 
Issuance of common stock in private offering, net of issuance costs
  - 
  - 
  - 
  - 
  255,000 
  - 
  1,750 
  - 
  - 
  1,750 
Issuance of common stock for acquisition of Khrysos
  - 
  - 
  - 
  - 
  1,794,972 
  1 
  13,999 
  - 
  - 
  14,000 
Issuance of common stock for debt financing, net of issuance costs
  - 
  - 
  - 
  - 
  40,000 
  - 
  350 
  - 
  - 
  350 
Issuance of common stock for true-up shares
  - 
  - 
  - 
  - 
  44,599 
  - 
  281 
  - 
  - 
  281 
Issuance of common stock for convertible note financing, net of issuance costs
  - 
  - 
  - 
  - 
  61,000 
  - 
  293 
  - 
  - 
  293 
Issuance of common stock related to purchase of land - H&H
  - 
  - 
  - 
  - 
  153,846 
  - 
  1,200 
  - 
  - 
  1,200 
Issuance of common stock related to purchase of trademark - H&H
  - 
  - 
  - 
  - 
  100,000 
  - 
  750 
  - 
  - 
  750 
Issuance of common stock related to advance for working capital (note receivable) net of settlement of debt
  - 
  - 
  - 
  - 
  295,910 
  1 
  2,308 
  - 
  - 
  2,309 
Release of warrant liability upon exercise of warrants
  - 
  - 
  - 
  - 
  - 
  - 
    866 
  - 
  - 
    866 
Release of warrant liability upon reclassification of liability to equity
  - 
  - 
  - 
  - 
  - 
  - 
  1,494 
  - 
  - 
  1,494 
Warrant issued upon vesting for services
  - 
  - 
  - 
  - 
  - 
  - 
  1,656 
  - 
  - 
  1,656 
Dividends on preferred stock
  - 
  - 
  - 
  - 
  - 
  - 
  (14)
  - 
  - 
  (14)
Stock based compensation expense
  - 
  - 
  - 
  - 
  - 
  - 
  11,344 
  - 
  - 
  11,344 
Balance at March 31, 2019
  161,135 
 $- 
  129,437 
 $- 
  28,890,671 
 $29 
 $244,906 
 $57 
 $(196,023)
 $48,969 
 
 * The Unaudited Condensed Consolidated Statement of Stockholders’ Equity for the three months ended March 31, 2019 has been restated. See Note 2.
  
 
-4-
 
 
Youngevity International, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Stockholders' Equity
(In thousands, except shares)
 
 
 
 Series A
Preferred Stock
 
 
 Series B
Preferred Stock
 
 
 
Common Stock
 
 
 Additional
Paid-in
 
 
Accumulated
Other Comprehensive
 
 
 
Accumulated
 
 
Total
Stockholders'
 
 
 
Shares
 
 
Amount
 
 
Shares
 
 
Amount
 
 
Shares
 
 
Amount
 
 
Capital
 
 
Loss
 
 
Deficit
 
 
Equity
 
Balance at December 31, 2017
  161,135 
 $- 
  - 
 $- 
  19,723,285 
 $20 
 $171,405 
 $(281)
 $(163,693)
 $7,451 
Net loss
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  (2,308)
  (2,308)
Foreign currency translation adjustment
  - 
  - 
  - 
  - 
  - 
  - 
  - 
  201 
  - 
  201 
Issuance of Series B preferred stock, net of issuance cost
  - 
  - 
  381,173 
  - 
  - 
  - 
  3,289 
  - 
  - 
  3,289 
Issuance of common stock pursuant to the exercise of stock options and warrants
  - 
  - 
  - 
  - 
  437 
  - 
  2 
  - 
  - 
  2 
Issuance of common stock for services
  - 
  - 
  - 
  - 
  5,000 
  - 
  27 
  - 
  - 
  27 
Issuance of common stock for conversion of Notes – 2017 Notes
  - 
  - 
  - 
  - 
  1,577,033 
  1 
  6,542 
  - 
  - 
  6,545 
Dividends on preferred stock
  - 
  - 
  - 
  - 
  - 
  - 
  (3)
  - 
  - 
  (3)
Stock based compensation expense
  - 
  - 
  - 
  - 
  - 
  - 
  237 
  - 
  - 
  237 
Balance at March 31, 2018
  161,135 
 $- 
  381,173 
 $- 
  25,305,755 
 $21 
 $181,501 
 $(80)
 $(166,001)
 $15,441 
 
See accompanying notes to condensed consolidated financial statements.
  
 
-5-
 
 
Youngevity International, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Cash Flows
 (In thousands)
 
 
 
Three Months Ended
March 31,
 
 
 
2019
 
 
2018
 
Cash Flows from Operating Activities:
 
(Restated)*
 
 
 
 
Net loss
 $(12,260)
 $(2,308)
Adjustments to reconcile net loss to net cash used in operating activities:
    
    
Depreciation and amortization
  1,145 
  1,259 
Stock-based compensation expense
  11,344 
  237 
Amortization of debt discounts and issuance costs
  199 
  543 
Change in fair value of warrant derivative liability
  (1,486)
  (712)
Change in fair value of contingent acquisition debt
  - 
  (213)
Changes in inventory reserve
  159 
  - 
Extinguishment loss on debt
  - 
  1,082 
Equity issuance for services
  1,859 
  27 
Stock issuance for true-up shares
  281 
  - 
Deferred taxes
  - 
  137 
Changes in operating assets and liabilities, net of effect from business combinations:
    
    
Accounts receivable
  (3,369)
  (1,231)
Inventory
  (1,283)
  (1,139)
Prepaid expenses and other current assets
  (111)
  (484)
Accounts payable
  54 
  794 
Accrued distributor compensation
  854 
  259 
Deferred revenues
  (44)
  1,302 
Accrued expenses and other liabilities
  (2,173)
  (1,075)
Income taxes receivable
  - 
  95 
Net Cash Used in Operating Activities
  (4,831)
  (1,427)
 
    
    
Cash Flows from Investing Activities:
    
    
Acquisitions, net of cash acquired
  (425)
  (50)
Purchases of property and equipment
  (2,291)
  (106)
Net Cash Used in Investing Activities
  (2,716)
  (156)
 
    
    
Cash Flows from Financing Activities:
    
    
Proceeds from issuance of promissory notes, net of offering costs
  3,750 
  - 
Proceeds from private placement of common stock, net of offering costs
  2,267 
  3,289 
Proceeds from at-the-market-offering and exercise of stock options and warrants, net
  1,455 
  3 
Proceeds net of repayment on line of credit
  176 
  770 
Payments of notes payable
  (35)
  (58)
Payments of contingent acquisition debt
  (128)
  (10)
Payments of finance leases
  (368)
  (232)
Payments of dividends 
  (11)
  - 
Net Cash Provided by Financing Activities
  7,106 
  3,762 
 
    
    
Foreign Currency Effect on Cash
  102 
  201 
Net (decrease) increase in cash and cash equivalents
  (339)
  2,380 
Cash and Cash Equivalents, Beginning of Period
  2,879 
  673 
Cash and Cash Equivalents, End of Period
 $2,540 
 $3,053 
 
    
    
Supplemental Disclosures of Cash Flow Information
    
    
Cash paid during the period for:
    
    
Interest
 $1,034 
 $1,191 
Income taxes
 $- 
 $44 
 
    
    
Supplemental Disclosures of Noncash Investing and Financing Activities
    
    
Purchases of property and equipment funded by finance leases
 $- 
 $664 
Purchases of property and equipment funded by mortgage agreements
 $450 
 $- 
Fair value of stock issued for services (Note 11)
 $417 
 $- 
Fair value of stock issued for property and equipment (land)
 $1,200 
 $- 
Fair value of stock issued for purchase of intangibles (tradename)
 $750 
 $- 
Fair value of stock issued for note receivable, net of debt settlement
 $2,309 
 $- 
Fair value of stock issued in connection with the acquisition of Khrysos Global, Inc. (Note 5)
 $14,000 
 $- 
Dividends declared but not paid at the end of period (Note 11)
 $14 
 $- 
Acquisitions of net assets in exchange for contingent debt, net of purchase price adjustments
 $- 
 $1,877 
Fair value of warrants issued in connection with the Series B Preferred Stock Offering
 $- 
 $75 
Conversion of 2017 Notes to Common Stock
 $- 
 $7,254 
 
* The Unaudited Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2019 has been restated. See Note 2.
 
See accompanying notes to condensed consolidated financial statements.
  
 
-6-
 
 
Youngevity International, Inc. and Subsidiaries
Notes to Unaudited Condensed Consolidated Financial Statements
 
Note 1. Basis of Presentation and Description of Business
 
Basis of Presentation
 
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, certain information and footnote disclosures, normally included in financial statements prepared in accordance with generally accepted accounting principles, have been condensed or omitted pursuant to such rules and regulations.
 
Youngevity International, Inc. (the “Company”) consolidates all wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
 
The statements presented as of March 31, 2019 and for the three months ended March 31, 2019 and 2018 are unaudited. In the opinion of management, these financial statements reflect all normal recurring and other adjustments necessary for a fair presentation, and to make the financial statements not misleading. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2018, filed with the SEC on April 15, 2019. The results for interim periods are not necessarily indicative of the results for the entire year.
 
Nature of Business
 
Youngevity International, Inc. (the “Company”), founded in 1996, develops and distributes health and nutrition related products through its global independent direct selling network, also known as multi-level marketing, and sells coffee products to commercial customers.  During the year ended December 31, 2018 the Company operated in two business segments, its direct selling segment where products are offered through a global distribution network of preferred customers and distributors and its commercial coffee segment where products are sold directly to businesses. During the first quarter of 2019, the Company through the acquisition of the assets of Khrysos Global, Inc. added a third business segment to its operations, the commercial hemp segment. The Company's three segments are listed below:
 
Commercial coffee business is operated through CLR and its wholly owned subsidiary, Siles Plantation Family Group S.A. (“Siles”).
 
Domestic direct selling network is operated through the following (i) domestic subsidiaries: AL Global Corporation, 2400 Boswell LLC, MK Collaborative LLC, and Youngevity Global LLC and (ii) foreign subsidiaries: Youngevity Australia Pty. Ltd., Youngevity NZ, Ltd., Youngevity Mexico S.A. de CV, Youngevity Israel, Ltd., Youngevity Russia, LLC, Youngevity Colombia S.A.S, Youngevity International Singapore Pte. Ltd., Mialisia Canada, Inc. and Legacy for Life Limited (Hong Kong). The Company also operates through the BellaVita Group LLC, with operations in Taiwan, Hong Kong, Singapore, Indonesia, Malaysia and Japan. The Company also operates subsidiary branches of Youngevity Global LLC in the Philippines and Taiwan.
 
Commercial hemp business is operated through the Company’s wholly owned subsidiary, Khrysos Industries, Inc., a Delaware corporation. Khrysos Industries, Inc. acquired the assets of Khrysos Global Inc. a Florida corporation in February 2019 and the wholly-owned subsidiaries of Khrysos Global Inc., INXL Laboratories, Inc., a Florida corporation and INX Holdings, Inc., a Florida corporation.
 
Segment Information
 
The Company has three reportable segments: direct selling, commercial coffee, and commercial hemp. The direct selling segment develops and distributes health and wellness products through its global independent direct selling network also known as multi-level marketing. The commercial coffee segment is engaged in coffee roasting and distribution (specializing in gourmet coffee), mill processing of green coffee, and sales of green coffee. The commercial hemp segment manufactures proprietary systems to provide end-to-end extraction and processing that allow for the conversion of hemp feed stock into hemp oil and hemp extracts. The determination that the Company has three reportable segments is based upon the guidance set forth in Accounting Standards Codification (“ASC”) Topic 280, “Segment Reporting.”
 
 
 
 
 
-7-
 
 
During the three months ended March 31, 2019, the Company derived approximately 81.1% of its revenue from its direct selling segment and approximately 18.7% of its revenue from its commercial coffee segment. Commercial hemp segment revenues during the current quarter represented 0.2% of total revenues as it is newly acquired. During the three months ended March 31, 2018, the Company had two reportable segments and derived approximately 82% of its revenue from its direct selling segment and approximately 18% of its revenue from its commercial coffee segment.
 
 Liquidity and Going Concern
 
The accompanying condensed consolidated financial statements have been prepared and presented on a basis assuming the Company will continue as a going concern. The Company has sustained significant losses during the three months ended March 31, 2019 and 2018 of approximately $12,260,000 and $2,308,000, respectively. Net cash used in operating activities was approximately $4,831,000 and $1,427,000 for the three months ended March 31, 2019 and 2018, respectively. The Company does not currently believe that its existing cash resources are sufficient to meet the Company’s anticipated needs over the next twelve months from the date hereof. Based on its current cash levels and its current rate of cash requirements, the Company will need to raise additional capital and/or will need to further reduce its expenses from current levels. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
 
The Company anticipates that revenues will grow, and it intends to make necessary cost reductions related to international operations that are not performing well and reduce non-essential expenses.
 
The Company is also considering multiple other fund-raising alternatives.  
 
On March 18, 2019, the Company entered into a two-year Secured Promissory Note (the “Note” or “Notes”) with two (2) accredited investors that had a substantial pre-existing relationship with the Company pursuant to which the Company raised cash proceeds of $2,000,000. In consideration of the Notes, the Company issued 20,000 shares of the Company’s common stock par value $0.001 for each $1,000,000 invested as well as for each $1,000,000 invested five-year warrants to purchase 20,000 shares of the Company’s common stock at a price per share of $6.00. The Notes pay interest at a rate of eight percent (8%) per annum and interest is paid quarterly in arrears with all principal and unpaid interest due at maturity on March 18, 2021.
 
On February 15, 2019 and on March 10, 2019, the Company closed its first and second tranches of its 2019 January Private Placement debt offering, respectively, pursuant to which the Company offered for sale notes in the principal amount of a minimum of $100,000 and a maximum of notes in the principal amount $10,000,000 (the “2019 PIPE Notes”), with each investor receiving 2,000 shares of common stock for each $100,000 invested. The Company entered into subscription agreements with thirteen (13) accredited investors that had a substantial pre-existing relationship with the Company pursuant to which the Company received aggregate gross proceeds of $2,440,000 and issued the 2019 PIPE Notes in the aggregate principal amount of $2,440,000 and an aggregate of 48,800 shares of common stock. The placement agent received 12,200 shares of common stock in aggregate for the first and second tranches. The placement agent will receive up to 50,000 shares of common stock in the offering. Each 2019 PIPE Note matures 24 months after issuance, bears interest at a rate of six percent (6%) per annum, and the outstanding principal is convertible into shares of common stock at any time after the 180th day anniversary of the issuance of the 2019 PIPE Note, at a conversion price of $10 per share (subject to adjustment for stock splits, stock dividends and reclassification of the common stock).
 
On February 6, 2019, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with one accredited investor that had a substantial pre-existing relationship with the Company pursuant to which the Company sold 250,000 shares of the Company’s common stock, par value $0.001 per share, at an offering price of $7.00 per share. Pursuant to the Purchase Agreement, the Company also issued to the investor a three-year warrant to purchase 250,000 shares of common stock at an exercise price of $7.00. The proceeds to the Company were $1,750,000. Consulting fees for arranging the Purchase Agreement include the issuance of 5,000 shares of restricted shares of the Company’s common stock, par value $0.001 per share, and 100,000 3-year warrants priced at $10.00. No cash commissions were paid.
  
 
 
-8-
 
 
On January 7, 2019, the Company entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with The Benchmark Company, LLC (“Benchmark”), as sales agent, pursuant to which the Company may sell from time to time, at its option, shares of its common stock, par value $0.001 per share, through Benchmark, as sales agent (the “Sales Agent”), for the sale of up to $60,000,000 of shares of the Company’s common stock. The Company is not obligated to make any sales of common stock under the ATM Agreement and the Company cannot provide any assurances that it will issue any shares pursuant to the ATM Agreement. The Company will pay the Sales Agent 3.0% commission of the gross sales proceeds. During the three months ended March 31, 2019, the Company sold a total of 1,000 shares of common stock under the ATM Agreement.
 
Depending on market conditions, there can be no assurance that additional capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company or to its stockholders.
 
Failure to raise additional funds from the issuance of equity securities and failure to implement cost reductions could adversely affect the Company’s ability to operate as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.
  
Use of Estimates
 
The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense for each reporting period. Estimates are used in accounting for, among other things, allowances for doubtful accounts, deferred taxes and related valuation allowances, fair value of derivative liabilities, uncertain tax positions, loss contingencies, fair value of options granted under the Company’s stock-based compensation plan, fair value of assets and liabilities acquired in business combinations, finance leases, asset impairments, estimates of future cash flows used to evaluate impairments, useful lives of property, equipment and intangible assets, value of contingent acquisition debt, inventory obsolescence, and sales returns.  
 
Actual results may differ from previously estimated amounts and such differences may be material to the consolidated financial statements. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected prospectively in the period they occur.
 
Cash and Cash Equivalents
 
The Company considers only its monetary liquid assets with original maturities of three months or less as cash and cash equivalents.
 
Related Party Transactions
 
Richard Renton
 
Richard Renton is a member of the Board of Directors and owns and operates WVNP, Inc., a supplier of certain inventory items sold by the Company.  The Company made purchases of approximately $8,000 and $54,000 from WVNP Inc., for the three months ended March 31, 2019 and 2018, respectively.
 
Carl Grover
 
Mr. Grover is the sole beneficial owner of in excess of five percent (5%) of the Company’s outstanding common shares. On December 13, 2018, CLR, entered into a Credit Agreement with Mr. Grover (the “Credit Agreement”) pursuant to which CLR borrowed $5,000,000 from Mr. Grover and in exchange issued to him a $5,000,000 credit note (“Credit Note”) secured by its green coffee inventory under a Security Agreement, dated December 13, 2018 (the “Security Agreement”), with Mr. Grover and CLR’s subsidiary, Siles Family Plantation Group S.A. (“Siles”), as guarantor, and Siles executed a separate Guaranty Agreement (“Guaranty”). The Company issued to Mr. Grover a four-year warrant to purchase 250,000 shares of our common stock, exercisable at $6.82 per share, and a four-year warrant to purchase 250,000 shares of the Company’s common stock, exercisable at $7.82 per share, pursuant to a Warrant Purchase Agreement, dated December 13, 2018, with Mr. Grover. (See Note 7 below.)
 
 
 
-9-
 
 
Paul Sallwasser
 
Mr. Paul Sallwasser is a member of the board directors and prior to joining the Company’s Board of Directors he acquired a note (the “2014 Note”) issued in the Company’s private placement consummated in 2014 (the “2014 Private Placement”) in the principal amount of $75,000 convertible into 10,714 shares of common stock and a warrant (the “2014 Warrant”) issued, in the 2014 Private Placement, exercisable for 14,673 shares of common stock. Prior to joining the Company’s Board of Directors, Mr. Sallwasser acquired in the 2017 Private Placement a 2017 Note in the principal amount of approximately $38,000 convertible into 8,177 shares of common stock and a warrant (the “2017 Warrant”) issued, in the 2017 Private Placement, exercisable for 5,719 shares of common stock. Mr. Sallwasser also acquired in the 2017 Private Placement in exchange for the “2015 Note” that he acquired in the Company’s private placement consummated in 2015 (the “2015 Private Placement”), a 2017 Note in the principal amount of $5,000 convertible into 1,087 shares of common stock and a 2017 Warrant exercisable for 543 shares of common stock. On March 30, 2018, the Company completed its Series B Offering, and in accordance with the terms of the 2017 Notes, Mr. Sallwasser’s 2017 Notes converted to 9,264 shares of the Company’s common stock.
 
2400 Boswell LLC
 
In March 2013, the Company acquired 2400 Boswell for approximately $4,600,000. 2400 Boswell is the owner and lessor of the building occupied by the Company for its corporate office and warehouse in Chula Vista, California. The purchase was from an immediate family member of the Company’s Chief Executive Officer and consisted of approximately $248,000 in cash, approximately $334,000 of debt forgiveness and accrued interest, and a promissory note of approximately $393,000, payable in equal payments over 5 years and bears interest at 5.0%.  Additionally, the Company assumed a long-term mortgage of $3,625,000, payable over 25 years with an initial interest rate of 5.75%. The interest rate is the prime rate plus 2.5%. The current interest rate as of March 31, 2019 was 7.75%. The lender will adjust the interest rate on the first calendar day of each change period or calendar quarter. The Company and its Chief Executive Officer are both co-guarantors of the mortgage. As of March 31, 2019, the balance on the long-term mortgage is approximately $3,198,000 and the balance on the promissory note is zero.
 
Other Relationship Transactions
 
Hernandez, Hernandez, Export Y Company and H&H Coffee Group Export Corp.
 
The Company’s commercial coffee segment, CLR, is associated with Hernandez, Hernandez, Export Y Company (“H&H”), a Nicaragua company, through sourcing arrangements to procure Nicaraguan grown green coffee beans. As part of the 2014 Siles acquisition, CLR engaged the owners of H&H, Alain Piedra Hernandez (“Mr. Hernandez”) and Marisol Del Carmen Siles Orozco (“Ms. Orozco”), as employees to manage Siles.
 
H&H is a sourcing agent that purchases raw green coffee beans from the local producers in Nicaragua and supplies CLR’s mill with unprocessed green coffee for processing. CLR does not have a direct relationship with the local producers and is dependent on H&H to negotiate agreements with local producers for the supply and provide to CLR’s mill raw unprocessed green coffee to CLR in a timely and efficient manner. Substantially all the green coffee processed through the Siles mill was coffee assigned to CLR for processing. In addition, during 2018, CLR sold green coffee beans to H&H Coffee Group Export Corp., (“H&H Export”), a Florida based company which is affiliated with H&H. In consideration for H&H's sourcing of green coffee for processing within CLR’s mill, CLR and H&H share in the green coffee profit from milling operations.
 
CLR made purchases from H&H of approximately $2,576,000 of green coffee for the three months ended March 31, 2019, for use in the Company’s Miami roasting facilities. There were no purchases of green coffee from H&H to be sold to other third parties during the three months ended March 31, 2019.
 
CLR made purchases from H&H of approximately $3,734,000 of green coffee for the three months ended March 31, 2018, for use in the Company’s Miami roasting facilities and for use in selling processed green coffee to third parties.
 
During the three months ended March 31, 2019, CLR recorded net revenues from processing services of approximately $4,826,000. There was no processing service revenue during the three months ended March 31, 2018.
 
During the three months ended March 31, 2018, CLR recorded the sale of processed green coffee beans, to H&H Export as gross revenue of $2,443,000. There were no processed green coffee bean sales, to H&H Export during the three months ended March 31, 2019.
 
 
 
-10-
 
 
In May 2017, the Company entered a settlement agreement with Alain Piedra Hernandez, one of the owners of H&H and the operating manager of Siles, who was issued a non-qualified stock option for the purchase of 75,000 shares of the Company’s common stock at a price of $2.00 with an expiration date of three years, in lieu of an obligation due from the Company to H&H as relates to a Sourcing and Supply Agreement with H&H. During the period ended September 30, 2017 the Company replaced the non-qualified stock option and issued a warrant agreement with the same terms. There was no financial impact related to the cancellation of the option and the issuance of the warrant. As of March 31, 2019, the warrant remains outstanding.
 
In December 2018, CLR advanced $5,000,000 to H&H Export to provide services in support of a 5-year contract for the sale and processing of 41 million pounds of green coffee beans on an annual basis. The services include providing hedging and financing opportunities to producers and delivering harvested coffee to the Company’s mills.  On March 31, 2019, this advance was converted to a $5,000,000 loan agreement and bears interest at 9% per annum and is due and payable by H&H Export at the end of each year’s harvest season, but no later than October 31 for any harvest year. The loan is secured by H&H Export’s hedging account with INTL FC Stone, trade receivables, green coffee inventory in the possession of H&H Export and all green coffee contracts.
 
Mill Construction Agreement
 
On January 15, 2019, CLR entered into the CLR Siles Mill Construction Agreement (the “Mill Construction Agreement”) with H&H and H&H Export, Alain Piedra Hernandez (“Hernandez”) and Marisol Del Carmen Siles Orozco (“Orozco”), together with H&H, H&H Export, Hernandez and Orozco, collectively referred to as the Nicaraguan Partner, pursuant to which the Nicaraguan Partner agreed to transfer a 45 acre tract of land in Matagalpa, Nicaragua (the “Property”) to be owned 50% by the Nicaraguan Partner and 50% by CLR. In consideration for the land acquisition the Company issued to H&H Export, 153,846 shares of common stock. In addition, the Nicaraguan Partner and CLR agreed to contribute $4,700,000 each toward the construction of a processing plant, office, and storage facilities (“Mill”) on the property for processing coffee in Nicaragua. As of March 31, 2019, the Company paid $1,350,000 towards construction of a mill, which is included in construction in process within property and equipment, net on the Company's condensed consolidated balance sheet. 
 
Amendment to Operating and Profit-Sharing Agreement
 
On January 15, 2019, CLR entered into an amendment to the March 2014 operating and profit-sharing agreement with the owners of H&H. CLR previously engaged Hernandez and Orozco, the owners of H&H as employees to manage Siles. In addition, CLR and H&H, Hernandez and Orozco have agreed to restructure their profit-sharing agreement in regard to profits from green coffee sales and processing that increases the CLR’s profit participation by an additional 25%. Under the new terms of the agreement with respect to profit generated from green coffee sales and processing from La Pita, a leased mill, or the new mill, now will provide for a split of profits of 75% to CLR and 25% to the Nicaraguan Partner, after certain conditions are met. The Company issued 295,910 shares of the Company’s common stock to H&H Export to pay for certain working capital, construction and other payables. In addition, H&H Export has sold to CLR its espresso brand Café Cachita in consideration of the issuance of 100,000 shares of the Company’s common stock. Hernandez and Orozco are employees of CLR. The shares of common stock issued were valued at $7.50 per share.
 
Revenue Recognition
 
The Company recognizes revenue from product sales under the following five steps are completed: i) Identify the contract with the customer; ii) Identify the performance obligations in the contract; iii) Determine the transaction price; iv) Allocate the transaction price to the performance obligations in the contract; and v) Recognize revenue when (or as) each performance obligation is satisfied (see Note 4, below).
 
Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. Revenue is recognized net of allowances for returns and any taxes collected from customers, which are subsequently remitted to governmental authorities.
 
 
 
-11-
 
 
The transaction price for all sales is based on the price reflected in the individual customer's contract or purchase order. Variable consideration has not been identified as a significant component of the transaction price for any of our transactions.
 
Independent distributors receive compensation which is recognized as Distributor Compensation in the Company’s consolidated statements of operations. Due to the short-term nature of the contract with the customers, the Company accrues all distributor compensation expense in the month earned and pays the compensation the following month.
 
The Company also charges fees to become a distributor, and earn a position in the network genealogy, which are recognized as revenue in the period received. The Company’s distributors are required to pay a one-time enrollment fee and receive a welcome kit specific to that country or region that consists of forms, policy and procedures, selling aids, access to the Company’s distributor website and a genealogy position with no down line distributors.
 
The Company has determined that most contracts will be completed in less than one year. For those transactions where all performance obligations will be satisfied within one year or less, the Company is applying the practical expedient outlined in ASC 606-10-32-18. This practical expedient allows the Company not to adjust promised consideration for the effects of a significant financing component if the Company expects at contract inception the period between when the Company transfers the promised good or service to a customer and when the customer pays for that good or service will be one year or less. For those transactions that are expected to be completed after one year, the Company has assessed that there are no significant financing components because any difference between the promised consideration and the cash selling price of the good or service is for reasons other than the provision of financing.
 
Deferred Revenues and Costs
 
As of March 31, 2019 and December 31, 2018, the balance in deferred revenues was approximately $2,268,000 and $2,312,000, respectively. Deferred revenue related to the Company’s direct selling segment is attributable to the Heritage Makers product line and also for future Company convention and distributor events.
 
Deferred revenues related to Heritage Makers were approximately $2,095,000 and $2,153,000, as of March 31, 2019, and December 31, 2018, respectively. The deferred revenue represents Heritage Maker’s obligation for points purchased by customers that have not yet been redeemed for product. Cash received for points sold is recorded as deferred revenue. Revenue is recognized when customers redeem the points and the product is shipped.
 
Deferred costs relate to Heritage Makers prepaid commissions that are recognized in expense at the time the related revenue is recognized. As of March 31, 2019 and 2018, the balance in deferred costs was approximately $338,000 and $364,000, respectively, and is included in prepaid expenses and current assets.
 
Deferred revenues related to pre-enrollment in upcoming conventions and distributor events of approximately $173,000 and $159,000 as of March 31, 2019 and December 31, 2018, respectively, relate primarily to the Company’s 2019 and 2018 events. The Company does not recognize this revenue until the conventions or distributor events occur.
 
Plantation Costs
 
The Company’s commercial coffee segment includes the results of Siles, which is a 500-acre coffee plantation and a dry-processing facility located on 26 acres located in Matagalpa, Nicaragua. Siles is a wholly-owned subsidiary of CLR, and the results of CLR include the depreciation and amortization of capitalized costs, development and maintenance and harvesting costs of Siles. In accordance with GAAP, plantation maintenance and harvesting costs for commercially producing coffee farms are charged against earnings when sold. Deferred harvest costs accumulate and are capitalized throughout the year and are expensed over the remainder of the year as the coffee is sold. The difference between actual harvest costs incurred and the amount of harvest costs recognized as expense is recorded as either an increase or decrease in deferred harvest costs, which is reported as an asset and included with prepaid expenses and other current assets in the condensed consolidated balance sheets. Once the harvest is complete, the harvest costs are then recognized as the inventory value. Deferred costs associated with the harvest as of March 31, 2019 and December 31, 2018 are approximately zero and $400,000, respectively, and are included in prepaid expenses and other current assets on the Company’s balance sheets.
 
 
 
-12-
 
 
Stock-based Compensation
 
The Company accounts for stock-based compensation in accordance with ASC Topic 718, “Compensation – Stock Compensation,” which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the vesting period of the equity grant.
 
The Company accounts for equity instruments issued to non-employees in accordance with authoritative guidance for equity-based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value, determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered.
 
Income Taxes
 
The Company accounts for income taxes in accordance with ASC Topic 740, "Income Taxes," under the asset and liability method which includes the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this approach, deferred taxes are recorded for the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial statement and tax basis of assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. The effects of future changes in income tax laws or rates are not anticipated.
 
Income taxes for the interim periods are computed using the effective tax rates estimated to be applicable for the full fiscal year, as adjusted for any discrete taxable events that occur during the period.
 
The Company files income tax returns in the United States (“U.S.”) on a federal basis and in many U.S. state and foreign jurisdictions. Certain tax years remain open to examination by the major taxing jurisdictions to which the Company is subject.
 
Commitments and Contingencies
 
The Company is from time to time, the subject of claims and suits arising out of matters related to the Company’s business. The Company is party to litigation at the present time and may become party to litigation in the future. In general, litigation claims can be expensive, and time consuming to bring or defend against and could result in settlements or damages that could significantly affect financial results. It is not possible to predict the final resolution of the current litigation to which the Company is party to, and the impact of certain of these matters on the Company’s business, results of operations, and financial condition could be material. Regardless of the outcome, litigation has adversely impacted the Company’s business because of defense costs, diversion of management resources and other factors
 
Recently Issued Accounting Pronouncements
 
In August 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2018-15, Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. Subtopic 350-40 clarifies the accounting for implementation costs of a hosting arrangement that is a service contract and aligns that accounting, regardless of whether the arrangement conveys a license to the hosted software. The amendments in this update are effective for reporting periods beginning after December 15, 2019, with early adoption permitted. The Company does not expect this new guidance to have a material impact on its condensed consolidated financial statements.
 
 
 
-13-
 
 
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. Topic 820 removes or modifies certain current disclosures and adds additional disclosures. The changes are meant to provide more relevant information regarding valuation techniques and inputs used to arrive at measures of fair value, uncertainty in the fair value measurements, and how changes in fair value measurements impact an entity's performance and cash flows. Certain disclosures in Topic 820 will need to be applied on a retrospective basis and others on a prospective basis. Topic 820 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. The Company expects to adopt the provisions of this guidance on January 1, 2020 and is currently evaluating the impact that Topic 820 will have on its related disclosures.
 
In January 2017, the FASB issued ASU No. 2017-04, Intangibles — Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. This ASU simplifies the test for goodwill impairment by removing Step 2 from the goodwill impairment test. Companies will now perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount, recognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value not to exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendments in this update are effective for goodwill impairment tests in fiscal years beginning after December 15, 2019 for public companies, with early adoption permitted for goodwill impairment tests performed after January 1, 2017. The Company does not expect this new guidance to have a material impact on its condensed consolidated financial statements.
 
Recently Adopted Accounting Pronouncements
 
In February 2018, the FASB issued Accounting Standards Update ASU No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220), Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, Topic 220. The amendments in this Update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act (H.R.1) (the Act). Consequently, the amendments eliminate the stranded tax effects resulting from the Act and will improve the usefulness of information reported to financial statement users. However, because the amendments only relate to the reclassification of the income tax effects of the Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. The amendments in this Update also require certain disclosures about stranded tax effects. Topic 220 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company adopted the provisions of this guidance on January 1, 2019 and the adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.
 
In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Topic 260 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted classified as liabilities. A company will recognize the value of a down round feature only when it is triggered, and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, such as warrants, an entity will treat the value of the effect of the down round, when triggered, as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in Topic 260 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company adopted ASU No. 2017-11 effective January 1, 2019 and determined that it’s 2018 warrants were to no longer be classified as a derivative, as a result of the adoption and subsequent change in classification of the 2018 warrants, the company reclassed approximately $1,494,000 of warrant derivative liability to equity.
 
 
 
-14-
 
 
In February 2016, FASB established Topic 842, Leases, by issuing ASU No. 2016-02, Leases (Topic 842) which required lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; ASU No. 2018-11, Targeted Improvements; ASU No. 2018-20, Narrow-Scope Improvements for Lessors; and ASU 2019-01, Codification Improvements. The new standard establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The amendments were adopted by the Company on January 1, 2019. A modified retrospective transition approach is required, applying the standard to all leases existing at the date of initial application. The Company elects to use its effective date as its date of initial application. Consequently, financial information will not be updated, and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company elected the “package of practical expedients”, which permits the Company not to reassess under the new standard prior conclusions about lease identification, lease classification and initial direction costs. In addition, the Company elected the practical expedient to use hindsight when determining lease terms.  The practicable expedient pertaining to land easement is not applicable to the Company. The Company continues to assess all of the effects of adoption, with the most significant effect relating to the recognition of new ROU assets and lease liabilities on the Company’s balance sheet for real estate operating leases.  The Company adopted the provisions of this guidance on January 1, 2019 and accordingly recognized additional operating liabilities of approximately $5,509,000 with corresponding ROU assets of the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases.
 
Following the expiration of the Company’s Emerging Growth Company filing status (“EGC”) on December 31, 2018 the Company adopted the following accounting pronouncements effective January 1, 2018.
 
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), to supersede nearly all existing revenue recognition guidance under GAAP. Topic 606 also requires new qualitative and quantitative disclosures, including disaggregation of revenues and descriptions of performance obligations. The Company adopted the provision of this guidance using the modified retrospective approach. The Company has performed an assessment of its revenue contracts as well as worked with industry participants on matters of interpretation and application and has not identified any material changes to the timing or amount of its revenue recognition under Topic 606. The Company’s accounting policies did not change materially as a result of applying the principles of revenue recognition from Topic 606 and are largely consistent with existing guidance and current practices applied by the Company. (See Note 4, below.)
 
Note 2. Restatement of previously reported unaudited condensed consolidated financial statements
 
Background and Effects of the Restatement
 
During the Company’s 2019 annual audit, the Company reviewed revenues related to CLR specifically the 2019 green coffee sales program, for sales made by the Company to its joint venture partner, H&H Coffee Group Export Corp. (“H&H Export”). These sales were originally recorded at gross, along with the respective cost of revenue.
 
As part of the review, the Company assessed whether the 2019 green coffee sales to H&H Export depicted the transfer of promised goods or services to H&H Export in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The following five steps were applied to review if the core revenue recognition principles were met as such the Company concluded it had not met all the criteria when applying these steps:
 
Step 1: Identify the contract with the customer
 
Step 2: Identify the performance obligations in the contract
 
Step 3: Determine the transaction price
 
Step 4: Allocate the transaction price to the performance obligations in the contract
 
Step 5: Recognize revenue when the company satisfies a performance obligation
 
 
 
-15-
 
 
During this review process the Company focused on identifying the performance obligations in the contracts with H&H Export (the provider of the “wet” green coffee and the buyer of the processed coffee). The Company’s assessment indicated that according to the underlying terms and conditions of the contracts that CLR entered into with H&H Export, that CLR had been assigned the green coffee beans as coffee was delivered to its mill processing facility. Assignment of the coffee is defined as taking of physical possession of the green coffee for the purpose of processing the green coffee. Under the assignment CLR was responsible for insuring all reasonable and necessary actions to ensure the coffee beans are safeguarded during processing at the Company’s coffee mill. CLR, however, does not take ownership and does not incur financial risk associated with the coffee as it is delivered to its mill for the purpose of processing. Based on the above assessment, management has determined that when CLR provides the processed green coffee to H&H export, the goods or services provided to H&H Export is the performance obligation to provide milling services for the green coffee. As such, the Company is the agent for the milling services.
 
Management has also determined that since the Company does not control the green coffee beans at the point of delivery to the mill, and that legal title to the green coffee beans is transferred momentarily, before the green coffee beans are sold back to H&H Export, that the Company is therefore an agent in sales transactions of green coffee beans to H&H Export.
  
Therefore, management has determined that for green coffee sales made by the Company to its joint venture partner, H&H Export, the Company should have recorded these sales at net of costs to purchase inventory, which reflects the value of the performance obligation to provide milling services. For the quarter ended March 31, 2019, the Company is restating its revenue for coffee sold to H&H Export at net.
 
On February 15, 2019, the Company and Khrysos Industries, Inc., closed its acquisition of Khrysos Global, Inc., detailed further in Note 5 to the unaudited condensed consolidated financial statements below. In conjunction with the Company’s 2019 annual audit the Company concluded that certain fixed assets acquired in the acquisition and the share price valuation for the common stock issued as consideration were not fairly valued as of the closing date including; i) $1,127,000 related to the certain fixed assets, and ii) $1,351,000 related to a change in the fair value of common stock issuance resulting in an increase to goodwill of $2,478,000 acquired and an adjusted aggregate purchase price if $15,894,000.
 
The tables below summarize the effects of the restatement on our (i) unaudited condensed consolidated balance sheet at March 31, 2019; (ii) unaudited condensed consolidated statement of operations for the three months ended March 31, 2019; and (iii) unaudited condensed consolidated statement of cash flows for the three months ended March 31, 2019. A summary of the effect of the restatement on the unaudited condensed consolidated statement of changes to stockholders’ equity for the three months ended March 31, 2019 are not presented because the impact to additional paid-in-capital are reflected below in the unaudited condensed consolidated balance sheet summaries.
 
 
 
-16-
 
 
Summary of Restatement – Unaudited Condensed Consolidated Balance Sheet
 
The effects of the restatement on the Company’s unaudited condensed consolidated balance sheet are as follows:
 
 
 
March 31, 2019
 
 
 
Previously Reported
 
 
Adjustments
 
 
Restated
 
ASSETS
 
 
 
 
 
 
 
 
 
Current Assets
 
 
 
 
 
 
 
 
 
       Cash and cash equivalents
 $2,540 
 $- 
 $2,540 
       Accounts receivable, trade
  21,629 
  (13,923)
  7,706 
       Income tax receivable
  75 
  - 
  75 
       Inventory
  46,805 
  (22,641)
  24,164 
       Notes receivable
  5,000 
  - 
  5,000 
       Prepaid expenses and Other current assets
  4,891 
  - 
  4,891 
Total current assets
  80,940 
  (36,564)
  44,376 
 
    
    
    
Property and equipment, net
  20,856 
  (1,127)
  19,729 
Operating lease right-of-use assets
  5,509 
  - 
  5,509 
Deferred tax assets
  148 
  - 
  148 
Intangible assets, net
  23,919 
  - 
  23,919 
Goodwill
  10,676 
  2,478 
  13,154 
Other assets – notes receivable
  949 
  - 
  949 
Total assets
 $142,997 
 (35,213)
 107,784 
 
    
    
    
LIABILITIES AND STOCKHOLDERS' EQUITY
    
    
    
 
    
    
    
Current Liabilities
    
    
    
Accounts payable
 $22,784 
 (13,923)
 8,861 
Accrued distributor compensation
  4,143 
  - 
  4,143 
Accrued expenses
  29,103 
  (22,641)
  6,462 
Deferred revenues
  2,268 
  - 
  2,268 
Line of credit
  2,432 
  - 
  2,432 
Other current liabilities
  535 
  - 
  535 
Operating lease liabilities, current portion
  745 
  - 
  745 
Finance lease liabilities, current portion
  978 
  - 
  978 
Notes payable, current portion
  158 
  - 
  158 
Convertible notes payable, current portion
  681 
  - 
  681 
Warrant derivative liability
  5,369 
  - 
  5,369 
Contingent acquisition debt, current portion
  792 
  - 
  792 
Total current liabilities
  69,988 
  (36,564)
  33,424 
 
    
    
    
Operating lease liabilities, net of current portion
  4,764 
  - 
  4,764 
Finance lease liabilities, net of current portion
  927 
  - 
  927 
Notes payable, net of current portion
  10,378 
  - 
  10,378 
Convertible notes payable, net of current portion
  1,981 
  - 
  1,981 
Contingent acquisition debt, net of current portion
  7,341 
  - 
  7,341 
Total liabilities
  95,379 
  (36,564)
  58,815 
 
    
    
    
Commitments and contingencies (Note 1)
    
    
    
 
    
    
    
Stockholders’ Equity
    
    
    
Preferred Stock, $0.001 par value: 5,000,000 shares authorized
  - 
  - 
  - 
    Convertible Preferred Stock, Series A - 161,135 shares issued and outstanding at March 31, 2019 and December 31, 2018
  - 
  - 
  - 
    Convertible Preferred Stock, Series B – 129,437 shares issued and outstanding at March 31, 2019 and December 31, 2018
  - 
  - 
  - 
Common Stock, $0.001 par value: 50,000,000 shares authorized; 28,890,671 and 25,760,708 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively
  29 
  - 
  29 
Additional paid-in capital
  243,555 
  1,351 
  244,906 
Accumulated deficit
  (196,023)
  - 
  (196,023)
Accumulated other comprehensive loss
  57 
  - 
  57 
    Total stockholders’ equity
  47,618 
  1,351 
  48,969 
 Total Liabilities and Stockholders’ Equity
 $142,997 
 (35,213)
 107,784 
 
 
 
-17-
 
 
Summary of Restatement – Unaudited Condensed Consolidated Statement of Operations
 
 The effects of the restatement on our unaudited condensed consolidated statement of operations are as follows:
 
 
 
Three Months Ended March 31, 2019
 
 
 
Previously Reported
 
 
Adjustments
 
 
Restated
 
Revenues
 $56,300 
 $(15,108)
 $41,192 
Cost of revenues
  29,451 
  (15,108)
  14,343 
Gross profit
  26,849 
  - 
  26,849 
Operating expenses
    
    
    
Distributor compensation
  14,890 
  - 
  14,890 
Sales and marketing
  4,019 
  - 
  4,019 
General and administrative
  19,881 
  - 
  19,881 
Total operating expenses
  38,790 
  - 
  38,790 
Loss from Operations
  (11,941)
  - 
  (11,941)
Interest expense, net
  (1,507)
  - 
  (1,507)
Change in fair value of warrant derivative liability
  1,486 
  - 
  1,486 
Total other expense, net
  (21)
  - 
  (21)
Net loss before income taxes
  (11,962)
  - 
  (11,962)
Income tax provision
  298 
  - 
  298 
Net loss
  (12,260)
  - 
  (12,260)
Preferred stock dividends
  (14)
  - 
  (14)
Net Loss Available to Common Stockholders
 $(12,274)
 $- 
 $(12,274)
 
    
    
    
Net loss per share, basic
 $(0.45)
 $- 
 $(0.45)
Net loss per share, diluted
 $(0.49)
 $- 
 $(0.49)
 
    
    
    
Weighted average shares outstanding, basic
  27,577,576 
  - 
  27,577,576 
Weighted average shares outstanding, diluted
  28,025,172 
  - 
  28,025,172 
 
 
 
-18-
 
 
Summary of Restatement – Unaudited Condensed Consolidated Statement of Cash Flows
 
The effect of the restatement on our unaudited condensed consolidated statement of cash flows are as follows:
 
 
 
Three Months Ended March 31, 2019
 
 
 
Previously Reported
 
 
Adjustments
 
 
Restated
 
 
 
 
 
 
 
 
 
 
 
Cash Flows from Operating Activities:
 
 
 
 
 
 
 
 
 
Net loss
 $(12,260)
 $- 
 $(12,260)
Adjustments to reconcile net loss to net cash used in operating activities:
    
    
    
Depreciation and amortization
  1,145 
  - 
  1,145 
Stock-based compensation expense
  11,344 
  - 
  11,344 
Amortization of debt discounts and issuance costs
  199 
  - 
  199 
Change in fair value of warrant derivative liability
  (1,486)
  - 
  (1,486)
Change in inventory reserve
  159 
  - 
  159 
Equity issuance for services
  1,859 
  - 
  1,859 
Stock issuance for true-up shares
  281 
  - 
  281 
Changes in operating assets and liabilities, net of effect from business combinations:
    
    
    
Accounts receivable
  (17,292)
  13,923 
  (3,369)
Inventory
  (23,924)
  22,641 
  (1,283)
Prepaid expenses and other current assets
  (111)
  - 
  (111)
Accounts payable
  13,977 
  (13,923)
  54 
Accrued distributor compensation
  854 
  - 
  854 
Deferred revenues
  (44)
  - 
  (44)
Accrued expenses and other liabilities
  20,468 
  (22,641)
  (2,173)
Net Cash Used in Operating Activities
  (4,831)
  - 
  (4,831)
 
    
    
    
Cash Flows from Investing Activities:
    
    
    
Acquisitions, net of cash acquired
  (425)
  - 
  (425)
Purchases of property and equipment
  (2,291)
  - 
  (2,291)
Net Cash Used in Investing Activities
  (2,716)
  - 
  (2,716)
 
    
    
    
Cash Flows from Financing Activities:
    
    
    
Proceeds from issuance of promissory notes, net of offering costs
  3,750 
  - 
  3,750 
Proceeds from private placement of common stock, net of offering costs
  2,267 
  - 
  2,267 
Proceeds from at-the-market-offering and exercise of stock options and warrants, net
  1,455 
  - 
  1,455 
Proceeds net of repayment on line of credit
  176 
  - 
  176 
Payments of notes payable
  (35)
  - 
  (35)
Payments of contingent acquisition debt
  (128)
  - 
  (128)
Payments of finance leases
  (368)
  - 
  (368)
Payments of dividends 
  (11)
  - 
  (11)
Net Cash Provided by Financing Activities
  7,106 
  - 
  7,106 
Foreign Currency Effect on Cash
  102 
  - 
  102 
Net decrease in cash and cash equivalents
  (339)
  - 
  (339)
Cash and Cash Equivalents, Beginning of Period
  2,879 
  - 
  2,879 
Cash and Cash Equivalents, End of Period
 $2,540 
 $- 
 $2,540 
 
    
    
    
Supplemental Disclosures of Cash Flow Information
    
    
    
Cash paid during the period for:
    
    
    
Interest
 $1,034 
 $- 
 $1,034 
Income taxes
 $- 
 $- 
 $- 
 
    
    
    
Supplemental Disclosures of Noncash Investing and Financing Activities
    
    
    
Purchases of property and equipment funded by finance leases
 $- 
 $- 
 $- 
Purchases of property and equipment funded by mortgage agreements
 $450 
 $- 
 $450 
Fair value of stock issued for services (Note 11)
 $417 
 $- 
 $417 
Fair value of stock issued for property and equipment (land)
 $1,200 
 $- 
 $1,200 
Fair value of stock issued for purchase of intangibles (tradename)
 $750 
 $- 
 $750 
Fair value of stock issued for note receivable, net of debt settlement
 $2,309 
 $- 
 $2,309 
Fair value of stock issued in connection with the acquisition of Khrysos Global, Inc. (Note 5) (1)
 $12,649 
 $1,351 
 $14,000 
Dividends declared but not paid at the end of period (Note 11)
 $14 
 $- 
 $14 
Acquisitions of net assets in exchange for contingent debt, net of purchase price adjustments
 $- 
 $- 
 $- 
Fair value of warrants issued in connection with the Series B Preferred Stock Offering
 $- 
 $- 
 $- 
Conversion of 2017 Notes to Common Stock
 $- 
 $- 
 $- 
 
(1)
The Fair value of stock issued in connection with the acquisition of Khrysos Global, Inc., was previously reported in Note 4 to the original filing of the Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 as filed with the SEC on May 20, 2019.
 
 
 
-19-
 
 
Note 3. Basic and Diluted Net Loss Per Share
 
Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share is computed by dividing net loss attributable to common stockholders by the sum of the weighted-average number of common shares outstanding during the period and the weighted-average number of dilutive common share equivalents outstanding during the period, using the treasury stock method. Dilutive common share equivalents are comprised of stock options, restricted stock, warrants, convertible preferred stock and common stock associated with the Company's convertible notes based on the average stock price for each period using the treasury stock method. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share.
 
Potentially dilutive securities for the three months ended March 31, 2019 were 12,882,194. Potentially dilutive securities were 7,321,334 for the three months ended March 31, 2018.
 
The calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of such securities are dilutive to loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of the warrants, net of tax from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method. During the three months ended March 31, 2019 and 2018, the Company recorded net of tax gain of $1,409,000 and $254,000, on the valuation of the Warrant Derivative Liability which has a dilutive impact on loss per share, respectively.
 
 
 
Three months ended
March 31,
(unaudited)
 
 
 
2019
 
 
2018
 
Loss per Share – Basic
 
 
 
 
 
 
Numerator for basic loss per share
 $(12,274,000)
 $(2,311,000)
Denominator for basic loss per share
  27,577,576 
  19,744,144 
Loss per common share – basic
 $(0.45)
 $(0.12)
 
    
    
Loss per Share – Diluted
    
    
Numerator for basic loss per share
 $(12,274,000)
 $(2,311,000)
Adjust: Fair value of dilutive warrants outstanding
  (1,409,000)
  (254,000)
Numerator for dilutive loss per share
 $(13,683,000)
 $(2,565,000)
 
    
    
Denominator for basic loss per share
  27,577,576 
  19,744,144 
Plus: Incremental shares underlying “in the money” warrants outstanding
  447,595 
  14,258 
Denominator for diluted loss per share
  28,025,172 
  19,758,402 
Loss per common share – diluted
 $(0.49)
 $(0.13)
 
Note 4.  Balance Sheet Account Details
 
Inventory and Cost of Revenues
 
Inventory is stated at the lower of cost or net realizable value, net of a valuation allowance. Cost is determined using the first-in, first-out method. The Company records an inventory reserve for estimated excess and obsolete inventory based upon historical turnover, market conditions and assumptions about future demand for its products. When applicable, expiration dates of certain inventory items with a definite life are taken into consideration.
 
 
 
-20-
 
 
Inventories consist of the following (in thousands):
 
 
 
As of
 
 
 
March 31,
2019
 
 
December 31,
2018
 
 
 
( Restated)*
 
 
 
 
Finished goods
 $14,948 
 $11,300 
Raw materials
  11,643 
  12,744 
Total inventory
  26,591 
  24,044 
Reserve for excess and obsolete
  (2,427)
  (2,268)
Inventory, net
 $24,164 
 $21,776 
 
Cost of revenues includes the cost of inventory, shipping and handling costs, royalties associated with certain products, transaction banking costs, warehouse labor costs and depreciation on certain assets. 
 
* Net inventory at March 31, 2019 has been restated. See Note 2.
  
Leases
 
Generally, the Company leases certain office space, warehouses, distribution centers, manufacturing centers, and equipment. A contract is or contains a lease if the contract conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration
 
In general, the Company’s leases include one or more options to renew, with renewal terms that generally vary from one to ten years. The exercise of lease renewal options is generally at the Company’s sole discretion. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.
 
The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
 
Leases with an initial term of twelve months or less are not recorded on the Company’s condensed consolidated balance sheets, and the Company does not separate nonlease components from lease components. The Company’s lease assets and liabilities recognized within its condensed consolidated balance sheets were as follows (in thousands):
 
 
 
March 31,
2019
 
Balance Sheet Location
ASSETS:
 
 
 
 
Operating lease right-of-use assets
 $5,509 
Operating lease right-of-use assets
Finance lease right-of-use assets
  1,330 
Property, plant, and equipment, net at cost, net of accumulated amortization (1)
Total lease assets
 $6,839 
 
LIABILITIES:
    
 
Current:
    
 
Operating lease liabilities
 $745 
Other current liabilities
Finance lease liabilities
  978 
Current portion of long-term debt
Non-current:
    
 
Operating lease liabilities
  4,764 
Non-current operating lease liabilities
Finance lease liabilities
  927 
Long-term debt, net of current portion
Total lease liabilities
 $7,714 
 
 
(1)
Finance lease assets are recorded net of accumulated amortization of approximately $522,000 as of March 31, 2019.
 
 
 
-21-
 
 
Lease cost is recognized on a straight-line basis over the lease term (in thousands):
 
 
 
March 31,
2019
 
Operating lease costs
 $271 
Finance lease cost
  - 
Amortization of right-of-use assets
  96 
Interest on lease liabilities
  37 
Net lease costs
 $404 
 
As of March 31, 2019, annual scheduled lease payments were as follows (in thousands):
 
 
 
Operating
Leases
 
 
Finance
Leases
 
2019
 $788 
 $1,086 
2020
  753 
  742 
2021
  688 
  204 
2022 
  648 
  9 
2023
  889 
  3 
Thereafter
  3,139 
  - 
Total lease payments
  6,905 
  2,044 
Less imputed interest
  1,396 
  139 
Present value of lease liabilities
 $5,509 
 $1,905 
 
Finance lease right-of-use assets are amortized over their estimated useful life, as the Company does believe that it is reasonably certain that options which transfer ownership will be exercised. In general, for the majority of the Company’s material leases, the renewal options are not included in the calculation of its right-of-use assets and lease liabilities, as the Company does not believe that it is reasonably certain that these renewal options will be exercised. Periodically, the Company assesses its leases to determine whether it is reasonably certain that these options and any renewal options could be reasonably expected to be exercised.
 
The majority of the Company’s leases are for real estate and equipment. In general, the individual lease contracts do not provide information about the rate implicit in the lease. Because the Company is not able to determine the rate implicit in its leases, it instead generally uses its incremental borrowing rate to determine the present value of lease liabilities. In determining its incremental borrowing rate, the Company reviewed the terms of its leases, its senior secured credit facility, swap rates, and other factors. The weighted-average remaining lease term and weighted-average discount rate used to calculate the present value of lease liabilities are as follows:
 
 
 
March 31,
2019
 
Weighted-average remaining lease terms:
 
 
 
       Operating leases
  5.8 
       Finance leases
  2.1 
Weighted-average remaining discount rate:
    
       Operating leases
  5.5%
       Finance leases
  9.1%
  
 
 
-22-
 
 
Revenue Recognition
 
Direct Selling
 
Direct distribution sales are made through the Company’s network (direct selling segment), which is a web-based global network of customers and distributors. The Company’s independent sales force markets a variety of products to an array of customers, through friend-to-friend marketing and social networking. The Company considers itself to be an e-commerce company whereby personal interaction is provided to customers by its independent sales network. Sales generated from direct distribution includes health and wellness, beauty product and skin care, scrap booking and story booking items, packaged food products and other service-based products.
 
Revenue is recognized when the Company satisfies its performance obligations under the contract. The Company recognizes revenue by transferring the promised products to the customer, with revenue recognized at shipping point, the point in time the customer obtains control of the products. The majority of the Company’s contracts have a single performance obligation and are short term in nature. Sales taxes in domestic and foreign jurisdictions are collected from customers and remitted to governmental authorities, all at the local level, and are accounted for on a net basis and therefore are excluded from revenues.
 
Commercial Coffee - Coffee Roaster
 
The Company engages in the commercial sale of roasted coffee through its subsidiary CLR, which is sold under a variety of private labels through major national sales outlets and to customers including cruise lines and office coffee service operators, and under its own Café La Rica brand, Josie’s Java House Brand and Javalution brands as well as through its distributor network within the direct selling segment.
  
Revenue is recognized when the title and risk of loss is passed to the customer under the terms of the shipping arrangement, typically, FOB shipping point. At this point the customer has a present obligation to pay, takes physical possession of the product, takes legal title to the product, bears the risks and rewards of ownership, and as such, revenue will be recognized at this point in time. Sales taxes in domestic and foreign jurisdictions are collected from customers and remitted to governmental authorities, all at the local level, and are accounted for on a net basis and therefore are excluded from revenues.
 
Commercial Coffee - Green Coffee
  
The commercial coffee segment includes the sale of green coffee beans, which are sourced from the Nicaraguan rainforest and providing milling serves to H&H.
  
Revenue is recognized when the title and risk of loss is passed to the customer under the terms of the shipping arrangement, typically, FOB shipping point. At this point the customer has a present obligation to pay, takes physical possession of the product, takes legal title to the product, bears the risks and rewards of ownership, and as such, revenue will be recognized at this point in time. Revenues derived from the sales of green coffee beans by the Company that it has milled, and it has determined it is the agent with regard to such green coffee beans is recorded at net of costs to purchase inventory or recorded to reflect only the revenue derived from the milling services provided. Sales taxes in domestic and foreign jurisdictions are collected from customers and remitted to governmental authorities, all at the local level, and are accounted for on a net basis and therefore are excluded from revenues.
 
Commercial Hemp
 
The commercial hemp segment provides end to end extraction and processing via the Company’s proprietary systems that allow for the conversion of hemp feed stock into hemp oil and hemp extracts.  The primary focus of the segment will be to generate revenue through sales of extraction services and end to end processing services for the conversion of Hemp and Hemp oil into sellable ingredients.  Additionally, the company offers various rental, sales, and service programs of the Company’s extraction and processing systems.
 
 
 
-23-
 
 
Revenue is recognized when the title and risk of loss is passed to the customer under the terms of the shipping arrangement, typically, FOB shipping point. At this point the customer has a present obligation to pay, takes physical possession of the product, takes legal title to the product, bears the risks and rewards of ownership, and as such, revenue will be recognized at this point in time. Sales taxes in domestic and foreign jurisdictions are collected from customers and remitted to governmental authorities, all at the local level, and are accounted for on a net basis and therefore are excluded from revenues.
 
The Company operates in three primary segments: the direct selling segment where products are offered through a global distribution network of preferred customers and distributors, the commercial coffee segment where products are sold directly to businesses and the Hemp segment.
 
The following table summarizes revenue disaggregated by segment (in thousands):
 
 
 
For the three months ended
March 31,
 
 
 
2019
 
 
2018
 
 
 
(Restated)* 
 
 
 
 
Direct selling
 $33,420 
 $35,311 
Commercial coffee:
    
    
Processed green coffee
  100 
  4,985 
Milling and processing services
  4,826 
  - 
Roasted coffee and other
  2,779 
  2,698 
Total commercial coffee
  7,705 
  7,683 
Commercial hemp
  67 
  - 
Total
 $41,192 
 $42,994 
 
* Revenue for the three months ended March 31, 2019 has been restated. See Note 2.
 
Contract Balances  
 
Timing of revenue recognition may differ from the timing of invoicing to customers. The Company records contract assets when performance obligations are satisfied prior to invoicing.
 
Contract liabilities are reflected as deferred revenues in current liabilities on the Company’s condensed consolidated balance sheets and includes deferred revenue and customer deposits. Contract liabilities relate to payments invoiced or received in advance of completion of performance obligations and are recognized as revenue upon the fulfillment of performance obligations. Contract Liabilities are classified as short-term as all performance obligations are expected to be satisfied within the next 12 months.
 
As of March 31, 2019 and December 31, 2018, the balance in deferred revenues was approximately $2,268,000 and $2,312,000, respectively. The Company records deferred revenue related to its direct selling segment which is primarily attributable to the Heritage Makers product line and represents Heritage Maker’s obligation for points purchased by customers that have not yet been redeemed for product. In addition, deferred revenues include future Company convention and distributor events.
 
Deferred revenue related to the commercial coffee segment represents deposits on customer orders that have not yet been completed and shipped. Revenue is recognized when the title and risk of loss is passed to the customer under the terms of the shipping arrangement FOB shipping point. (See Note 1, above.)
 
Of the deferred revenue from the year ended December 31, 2018, the Company recognized revenue of approximately $2,095,000 from the Heritage Makers product line during the three months ended March 31. 2019.
 
There were no deferred revenues associated with the commercial coffees segment and the commercial hemp as of March 31, 2019.
 
 
 
-24-
 
 
Note 5. Acquisitions and Business Combinations
 
The Company accounts for business combinations under the acquisition method and allocates the total purchase price for acquired businesses to the tangible and identified intangible assets acquired and liabilities assumed, based on their estimated fair values. When a business combination includes the exchange of the Company’s common stock, the value of the common stock is determined using the closing market price as of the date such shares were tendered to the selling parties. The fair values assigned to tangible and identified intangible assets acquired and liabilities assumed are based on management or third-party estimates and assumptions that utilize established valuation techniques appropriate for the Company’s industry and each acquired business. Goodwill is recorded as the excess, if any, of the aggregate fair value of consideration exchanged for an acquired business over the fair value (measured as of the acquisition date) of total net tangible and identified intangible assets acquired. A liability for contingent consideration, if applicable, is recorded at fair value as of the acquisition date. In determining the fair value of such contingent consideration, management estimates the amount to be paid based on probable outcomes and expectations on financial performance of the related acquired business. The fair value of contingent consideration is reassessed quarterly, with any change in the estimated value charged to operations in the period of the change. Increases or decreases in the fair value of the contingent consideration obligations can result from changes in actual or estimated revenue streams, discount periods, discount rates and probabilities that contingencies will be met.
 
During the three months ended March 31, 2019, the Company entered into one acquisition, which is detailed below. The acquisition was conducted in an effort to expand the Company’s operations into the field of commercial hemp business.
 
2019 Acquisitions
 
Khrysos Global, Inc.
 
On February 12, 2019, the Company and Khrysos Industries, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“KII”) entered into an Asset and Equity Purchase Agreement (the “AEPA”) with, Khrysos Global, Inc., a Florida corporation (“Seller”), Leigh Dundore (“LD”), and Dwayne Dundore (the “Representing Party”) for KII to acquire substantially all the assets (the “Assets”) of KGI and all the outstanding equity of INXL Laboratories, Inc., a Florida corporation (“INXL”) and INX Holdings, Inc., a Florida corporation (“INXH”). Seller, INXL and INXH provides end to end extraction and processing via the company’s proprietary systems that allow for the conversion of hemp feed stock into hemp oil and hemp extracts.  Additionally, KII offers various rental, sales, and service programs of KII’s extraction and processing systems.
 
The consideration payable for the assets and the equity of KGI, INXL and INXH is an aggregate of $16,000,000, to be paid as set forth under the terms of the AEPA and allocated between the Sellers and LD in such manner as they determine at their discretion.
 
At the closing on February 15, 2019, the Seller, LD and the Representing Party received an aggregate of 1,794,972 shares of the Company’s common stock which have a value of $14,000,000 for the purposes of the AEPA or $12,649,000 fair value for the acquisition valuation and $500,000 in cash. Thereafter, Seller, LD and the Representing Party are to receive an aggregate of: $500,000 in cash thirty (30) days following the date of closing; $250,000 in cash ninety (90) days following the date of closing; $250,000 in cash one hundred and eighty (180) days following the Date of closing; $250,000 in cash two hundred and seventy (270) days following the date of closing; and $250,000 in cash one (1) year following the date of closing.
  
In addition, the Company agreed to issue to Representing Party, subject to the approval of the holders of at least a majority of the issued and outstanding shares of the Company’s common stock and the approval of The Nasdaq Stock Market (collectively, the “Contingent Consideration Warrants”) consisting of six (6) six-year warrants, to purchase 500,000 shares of common stock each, for an aggregate of 3,000,000 shares of common stock at an exercise price of $10 per share exercisable upon reaching certain levels of cumulative revenue or cumulative net income before taxes by the business during the any of the years ending December 31, 2019, 2020, 2021, 2022, 2023 or 2024.
 
The AEPA contains customary representations, warranties and covenants of the Company, KII, the Seller, LD and the Representing Party. Subject to certain customary limitations, the Seller, LD and the Representing Party have agreed to indemnify the Company and KII against certain losses related to, among other things, breaches of the Seller’s, LD’s and the Representing Party’s representations and warranties, certain specified liabilities and the failure to perform covenants or obligations under the AEPA.
 
On February 28, 2019, KII purchased a 45-acre tract of land in Groveland, Florida, in central Florida, which KII intends to build a R&D facility, greenhouse and allocate a portion for farming.
 
 
 
-25-
 
 
Restatement Note - related to the Acquisition of Khrysos Global, Inc.
 
In conjunction with the Company’s 2019 annual audit the Company concluded that certain fixed assets acquired in the acquisition and the share price valuation for the common stock issued as consideration were not fairly valued as of the closing date February 15, 2019 including; a) $1,127,000 related to the certain fixed assets, and b) $1,351,000 related to a change in the fair value of common stock issuance resulting in an increase to goodwill of $2,478,000 acquired and an adjusted aggregate purchase price if $15,894,000. As such, the Company here restates its Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.
 
The Company has estimated fair value at the date of acquisition of the acquired tangible and intangible assets and liabilities as follows including the resulting adjustments in changes to the aggregate purchase price (in thousands):
 
 
 
 
Consideration as Originally Reported
 
 
Adjustments
 
 
 
Consideration as Currently Reported
 
Present value of cash consideration
 $1,894 $ 
 $- 
 $1,894 
Estimated fair value of common stock issued
  12,649 
  1,351 
  14,000 
Aggregate purchase price
 $14,543 
 $1,351 
 $15,894 
 
 
 The following table summarizes the estimated preliminary and as adjusted fair values of the assets acquired and liabilities assumed in February 2019 (in thousands):
 
 
 
 
Fair Value as Originally Reported
 
 
Adjustments
 
 
 
Fair Value as Currently Reported
 
Current assets
 $636 
 $- 
 $636 
Inventory
  1,264 
  - 
  1,264 
Property, plant and equipment
  2,260 
  (1,127)
  1,133 
Trademarks and trade name
  1,876 
  - 
  1,876 
Customer-related intangible
  5,629 
  - 
  5,629 
Non-compete intangible
  956 
  - 
  956 
Goodwill
  4,353 
  2,478 
  6,831 
Current liabilities
  (1,904)
  - 
  (1,904)
Notes payable
  (527)
  - 
  (527)
Net assets acquired
 $14,543 
 $1,351 
 $15,894 
 
The preliminary estimated fair value of intangible assets acquired in the amount of $8,461,000 was determined through the use of a third-party valuation firm using various income and cost approach methodologies. Specifically, the intangibles identified in the acquisition were trademarks and trade name, customer-related intangible and non-compete agreement. The trademarks and trade name, customer-related intangible and non-compete are being amortized over their estimated useful life of 8 years, 7 years and 6 years, respectively. The straight-line method is being used and is believed to approximate the time-line within which the economic benefit of the underlying intangible asset will be realized.
 
 
 
 
-26-
 
 
Goodwill acquired as currently reported of $6,831,000 is recognized as the excess purchase price over the acquisition-date fair value of net assets acquired. Goodwill is estimated to represent the synergistic values expected to be realized from the combination of the two businesses. The goodwill is expected to be deductible for tax purposes.
 
The Contingent Consideration Warrants discussed above are subject to vesting based upon the achievement of various sales milestones and only if the sellers do not terminate their services.  As such, the warrants were considered equity-based compensation for future services and not considered contingent consideration in the calculation of the purchase price.
 
The costs related to the acquisition are included in legal and accounting fees.
 
Revenues included in the consolidated statement of operations for the three months ended March 31, 2019 were approximately $67,000.
 
Note 6. Intangible Assets and Goodwill
 
Intangible Assets
 
Intangible assets are comprised of distributor organizations, trademarks and tradenames, customer relationships and internally developed software.  The Company's acquired intangible assets, which are subject to amortization over their estimated useful lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. An impairment loss is recognized when the carrying amount of an intangible asset exceeds its fair value.
 
Intangible assets consist of the following (in thousands):
 
 
 
March 31, 2019
 
 
December 31, 2018
 
 
 
 
Cost
 
 
Accumulated
Amortization
 
 
 
Net
 
 
 
Cost
 
 
Accumulated
Amortization
 
 
 
Net
 
Distributor organizations
 $14,559 
 $9,796 
 $4,763 
 $14,559 
 $9,575 
 $4,984 
Trademarks and trade names
  9,963 
  2,033 
  7,930 
  7,337 
  1,781 
  5,556 
Customer relationships
  16,028 
  5,895 
  10,133 
  10,398 
  5,723 
  4,675 
Internally developed software
  720 
  583 
  137 
  720 
  558 
  162 
Non-compete agreement
  956 
  - 
  956 
  - 
  - 
  - 
Intangible assets
 $42,226 
 $18,307 
 $23,919 
 $33,014 
 $17,637 
 $15,377 
  
Amortization expense related to intangible assets was approximately $670,000 and $827,000 for the three months ended March 31, 2019 and 2018, respectively.
 
Trade names, which do not have legal, regulatory, contractual, competitive, economic, or other factors that limit the useful lives are considered indefinite lived assets and are not amortized but are tested for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. As of March 31, 2019 and December 31, 2018, approximately $1,649,000 in trademarks from business combinations have been identified as having indefinite lives.
 
Goodwill
 
Goodwill is recorded as the excess, if any, of the aggregate fair value of consideration exchanged for an acquired business over the fair value (measured as of the acquisition date) of total net tangible and identified intangible assets acquired. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, “Intangibles — Goodwill and Other”, goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount of these assets may not be recoverable. The Company conducts annual reviews for goodwill and indefinite-lived intangible assets in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable.
 
 
 
-27-
 
 
The Company first assesses qualitative factors to determine whether it is more likely than not (a likelihood of more than 50%) that goodwill is impaired. After considering the totality of events and circumstances, the Company determines whether it is more likely than not that goodwill is not impaired.  If impairment is indicated, then the Company conducts the two-step impairment testing process. The first step compares the Company’s fair value to its net book value. If the fair value is less than the net book value, the second step of the test compares the implied fair value of the Company’s goodwill to its carrying amount. If the carrying amount of goodwill exceeds its implied fair value, the Company would recognize an impairment loss equal to that excess amount. The testing is generally performed at the “reporting unit” level. A reporting unit is the operating segment, or a business one level below that operating segment (referred to as a component) if discrete financial information is prepared and regularly reviewed by management at the component level. The Company has determined that its reporting units for goodwill impairment testing are the Company’s reportable segments. As such, the Company analyzes its goodwill balances separately for the commercial coffee reporting unit, the direct selling reporting unit and the commercial hemp reporting unit. The goodwill balance as of March 31, 2019 and December 31, 2018 is approximately $13,154,000 and $6,323,000, respectively, which includes an adjustment to the KII acquisition goodwill during the three months ended March 31, 2019, discussed above in Note 5, which increased the goodwill for KII in the amount of $2,478,000. There were no triggering events indicating impairment of goodwill or intangible assets during the three months ended March 31, 2019 and 2018.
 
Goodwill consists of the following (in thousands):
 
 
 
March 31,
2019
 
 
December 31,
2018
 
Goodwill, commercial coffee
 $3,314 
 $3,314 
Goodwill, direct selling
  3,009 
  3,009 
Goodwill, commercial hemp
  6,831 
  - 
Total goodwill
 $13,154 
 $6,323 
 
Note 7.  Notes Payable and Other Debt
 
Short-term Debt
 
On July 18, 2018, the Company entered into lending agreements (the “Lending Agreements”) with three (3) separate entities and received loans in the total amount of $1,907,000, net of loan fees to be paid back over an eight-month period on a monthly basis. Payments are comprised of principal and accrued interest with an effective interest rate between 15% and 20%. The Company’s outstanding balance related to the Lending Agreements was approximately $504,000 as of December 31, 2018 and was included in other current liabilities on the Company’s balance sheet as of December 31, 2018. During the quarter ended March 31, 2019 the loans were paid in their entirety and the outstanding loan balance was zero.
 
Notes Payable
 
Promissory Notes
 
On March 18, 2019, the Company entered into a two-year Secured Promissory Note (the “Note” or “Notes”) with two (2) accredited investors that had a substantial pre-existing relationship with the Company pursuant to which the Company raised cash proceeds of $2,000,000. In consideration of the Notes, the Company issued 20,000 shares of the Company’s common stock par value $0.001 for each $1,000,000 invested as well as for each $1,000,000 invested five-year warrants to purchase 20,000 shares of the Company’s common stock at a price per share of $6.00. The Notes pay interest at a rate of eight percent (8%) per annum and interest is paid quarterly in arrears with all principal and unpaid interest due at maturity on March 18, 2021.
 
The Company recorded debt discounts of approximately $139,000 related to the fair value of warrants issued in the transaction and $212,000 of transaction issuance costs to be amortized to interest expense over the life of the Notes. As of March 31, 2019, the remaining balance of the debt discounts is approximately $345,000. The Company recorded approximately $5,000 amortization of the debt discounts during the three months ended March 31, 2019 and is recorded as interest expense.
 
 
 
-28-
 
 
Credit Note
 
On December 13, 2018, the Company’s wholly owned subsidiary, CLR, entered into a Credit Agreement with Mr. Carl Grover pursuant to which CLR borrowed $5,000,000 from Mr. Grover and in exchange issued to him a $5,000,000 Credit Note (the “Credit Note”) secured by its green coffee inventory under a Security Agreement, dated December 13, 2018, with Mr. Grover and CLR’s subsidiary, Siles.  In connection with the Credit Agreement, the Company issued to Mr. Grover a four-year warrant to purchase 250,000 shares of its common stock, exercisable at $6.82 per share (“Warrant 1”), and a four-year warrant to purchase 250,000 shares of its common stock, exercisable at $7.82 per share (“Warrant 2”), pursuant to a Warrant Purchase Agreement, dated December 13, 2018, with Mr. Grover. The Company also entered into an Advisory Agreement with Ascendant Alternative Strategies, LLC (“Ascendant”), a third party not affiliated with Mr. Grover, in connection with the Credit Agreement, pursuant to which it agreed to pay to Ascendant a 3% fee on the transaction with Mr. Grover and issued to Ascendant (or it’s designees) a four-year warrant to purchase 50,000 shares of its common stock, exercisable at $6.33 per share.
 
Upon the occurrence of an event of default, the unpaid balance of the principal amount of this Credit Note together with all accrued but unpaid interest, may become, or may be declared to be, due and payable in the manner, upon the conditions and with the effect provided in the Credit Agreement. The Company determined that the contingent call (put) option meets the definition of a derivative (i.e., has an underlying, a notional amount, requires no initial investment, and can be net settled). Therefore, it must be separately measured at fair value with changes in fair value impacting current earnings.
 
Management has assessed the probability of a trigger event (i.e., the occurrence of an event of default, such amounts are declared due and payable or made automatically due and payable, in each case, in accordance with the terms of this Note) to be de minimis during the term of the Credit Note. As such, the fair value of the contingent put feature would have a de minimis value (i.e., there is no need to separately measure the contingent put feature, as assigning a probability of zero percent or near zero percent to the occurrence of an event of default would result in de minimis fair value for the feature). Management will reassess the probability of a trigger event at each reporting period during the term of the Credit Note.
 
The Company recorded debt discounts of approximately $1,469,000 related to the fair value of warrants issued in the transaction and $175,000 of transaction issuance costs to be amortized to interest expense over the life of the Credit Agreement. As of March 31, 2019, the remaining balance of the debt discounts is approximately $1,460,000. The Company recorded approximately $154,000 amortization of the debt discounts during the three months ended March 31, 2019 and is recorded as interest expense.
 
2400 Boswell Mortgage
 
In March 2013, the Company acquired 2400 Boswell for approximately $4,600,000. 2400 Boswell is the owner and lessor of the building occupied by the Company for its corporate office and warehouse in Chula Vista, California. The purchase was from an immediate family member of our Chief Executive Officer and consisted of approximately $248,000 in cash, $334,000 of debt forgiveness and accrued interest, and a promissory note of approximately $393,000, payable in equal payments over 5 years with interest at 5.0%.  Additionally, the Company assumed a long-term mortgage of $3,625,000, payable over 25 years with an initial interest rate of 5.75%. The interest rate is the prime rate plus 2.5%. As of March 31, 2019, the interest rate was 7.75%. The lender will adjust the interest rate on the first calendar day of each change period. The Company and its Chief Executive Officer are both co-guarantors of the mortgage. As of March 31, 2019, the balance on the long-term mortgage is approximately $3,198,000 and– the balance on the promissory note is zero.
 
M2C Purchase Agreement
 
In March 2007, the Company entered into an agreement to purchase certain assets of M2C Global, Inc., a Nevada corporation, for $4,500,000.  The agreement required payments totaling $500,000 in three installments during 2007, followed by monthly payments in the amount of 10% of the sales related to the acquired assets until the entire note balance is paid. As of March 31,2019 and December 31, 2018, the carrying value of the liability was approximately $1,061,000 and $1,071,000, respectively. The interest associated with the note for the three months ended March 31, 2019 and 2018 was minimal.
 
 
 
-29-
 
 
Khrysos Mortgage Notes
 
In conjunction with the Company’s acquisition of Khrysos, the Company assumed one interest only mortgage in the amounts of $350,000 (due in September 2021) that bears an interest rate of 8% and a second mortgage of approximately $177,000 (due in June 2023) that bears an interest rate of 7% per annum. Both properties are located in Florida. As of March 31, 2019, the remaining mortgage balances are approximately $527,000.
 
In February 2019, Khrysos purchased a 45-acre tract of land in Groveland, Florida, in central Florida for $750,000, which Khrysos intends to build a R&D facility, greenhouse and allocate a portion for farming. Khrysos paid approximately $303,000 down and assumed a mortgage of $450,000. The entire balance is due in February 2024 and bears interest at 6% per annum. As of March 31, 2019, the remaining mortgage balance is $450,000.
 
Other Notes
 
The Company’s other notes relate to loans for commercial vans at CLR in the amount of $90,000 as of March 31, 2019 which expire at various dates through 2023.
 
Line of Credit - Loan and Security Agreement
 
CLR had a factoring agreement (“Factoring Agreement”) with Crestmark Bank (“Crestmark”) related to accounts receivable resulting from sales of certain CLR products. On November 16, 2017, CLR entered into a new Loan and Security Agreement (“Agreement”) with Crestmark which amended and restated the original Factoring Agreement dated February 12, 2010 with Crestmark and subsequent agreement amendments thereto. CLR is provided with a line of credit related to accounts receivables resulting from sales of certain products that includes borrowings to be advanced against acceptable eligible inventory related to CLR. Effective December 29, 2017, CLR entered into a First Amendment to the Agreement, to include an increase in the maximum overall borrowing to $6,250,000. The loan amount may not exceed an amount which is the lesser of (a) $6,250,000 or (b) the sum of up (i) to 85% of the value of the eligible accounts; plus, (ii) the lesser of $1,000,000 or 50% of eligible inventory or 50% of (i) above, plus (iii) the lesser of $250,000 or eligible inventory or 75% of certain specific inventory identified within the Agreement.
 
The Agreement contains certain financial and nonfinancial covenants with which the Company must comply to maintain its borrowing availability and avoid penalties.
 
The outstanding principal balance of the Agreement will bear interest based upon a year of 360 days with interest being charged for each day the principal amount is outstanding including the date of actual payment. The interest rate is a rate equal to the prime rate plus 2.50% with a floor of 6.75%. As of March 31, 2019, the interest rate was 8.0%. In addition, other fees are incurred for the maintenance of the loan in accordance with the Agreement. Other fees may be incurred in the event the minimum loan balance of $2,000,000 is not maintained. The Agreement is effective until November 16, 2020.
 
The Company and the Company’s CEO, Stephan Wallach, have entered into a Corporate Guaranty and Personal Guaranty, respectively, with Crestmark guaranteeing payments in the event that the Company’s commercial coffee segment CLR were to default. In addition, the Company’s President and Chief Financial Officer, David Briskie, personally entered into a Guaranty of Validity representing the Company’s financial statements so long as the indebtedness is owing to Crestmark, maintaining certain covenants and guarantees.
 
The Company’s outstanding line of credit liability related to the Agreement was approximately $2,432,000 as of March 31, 2019 and $2,256,000 as of December 31, 2018.
 
Contingent Acquisition Debt
 
The Company has contingent acquisition debt associated with its business combinations.  The Company accounts for business combinations under the acquisition method and allocates the total purchase price for acquired businesses to the tangible and identified intangible assets acquired and liabilities assumed, based on their estimated fair values as of the acquisition date. A liability for contingent consideration, if applicable, is recorded at fair value as of the acquisition date and evaluated each period for changes in the fair value and adjusted as appropriate. (See Note 10 below.)
 
The Company’s contingent acquisition debt as of March 31, 2019 and December 31, 2018 is $8,133,000 and $8,261,000, respectively, and is attributable to debt associated with the Company’s direct selling segment.
 
 
 
-30-
 
 
Note 8. Convertible Notes Payable
 
Total convertible notes payable as of March 31, 2019 and December 31, 2018, net of debt discount outstanding consisted of the amount set forth in the following table (in thousands):
 
 
 
March 31,
2019
(unaudited)
 
 
December 31,
2018
 
8% Convertible Notes due July and August 2019 (2014 Notes), principal
 $750 
 $750 
Debt discounts
  (69)
  (103)
Carrying value of 2014 Notes
  681 
  647 
6% Convertible Notes due February and March 2021 (2019 PIPE Notes), principal
  2,400 
  - 
Debt discounts
  (459)
  - 
Carrying value of 2019 PIPE Notes
  1,941 
  - 
Total carrying value of convertible notes payable
 $2,622 
 $647 
 
July 2014 Private Placement
 
Between July 31, 2014 and September 10, 2014 the Company entered into Note Purchase Agreements (the “Note” or “Notes”) related to its private placement offering (“2014 Private Placement”) with seven accredited investors pursuant to which the Company raised aggregate gross proceeds of $4,750,000 and sold units consisting of five (5) year senior secured convertible Notes in the aggregate principal amount of $4,750,000 that are convertible into 678,568 shares of our common stock, at a conversion price of $7.00 per share, and warrants to purchase 929,346 shares of common stock at an exercise price of $4.60 per share. The Notes bear interest at a rate of eight percent (8%) per annum and interest is paid quarterly in arrears with all principal and unpaid interest due between July and September 2019.
 
The Company has the right to prepay the Notes at any time after the one-year anniversary date of the issuance of the Notes at a rate equal to 110% of the then outstanding principal balance and any unpaid accrued interest. The Notes are secured by Company pledged assets and rank senior to all debt of the Company other than certain senior debt that has been previously identified as senior to the convertible notes. Additionally, Stephan Wallach, the Company’s Chief Executive Officer, has also personally guaranteed the repayment of the Notes, subject to the terms of a Guaranty Agreement executed by him with the investors.  In addition, Mr. Wallach has agreed not to sell, transfer or pledge 1.5 million shares of the common stock that he owns so long as his personal guaranty is in effect.
  
On October 23, 2018, the Company entered into an agreement with Carl Grover to exchange (the “Debt Exchange”), subject to stockholder approval which was received on December 6, 2018, all amounts owed under the 2014 Note held by him in the principal amount of $4,000,000 which matures on July 30, 2019, for 747,664 shares of the Company’s common stock, at a conversion price of $5.35 per share and a four-year warrant to purchase 631,579 shares of common stock at an exercise price of $4.75 per share. Upon the closing the Company issued Ascendant Alternative Strategies, LLC, a FINRA broker dealer (or its designees), which acted as the Company’s advisor in connection with a Debt Exchange transaction, 30,000 shares of common stock in accordance with an advisory agreement and four-year warrants to purchase 80,000 shares of common stock at an exercise price of $5.35 per share and four-year warrants to purchase 70,000 shares of common stock at an exercise price of $4.75 per share.
 
The Company considered the guidance of ASC 470-20, Debt: Debt with Conversion and Other Options and ASC 470-60, Debt: Debt Troubled Debt Restructuring by Debtors and concluded that the 2014 Note held by Mr. Grover should be recognized as a debt modification for an induced conversion of convertible debt under the guidance of ASC 470-20. The Company recognized all remaining unamortized discounts of approximately $679,000 immediately subsequent to October 23, 2018 as interest expense, and the fair value of the warrants and additional shares issued as discussed above were recorded as a loss on the Debt Exchange in the amount of $4,706,000 during the year ended December 31, 2018 with the corresponding entry recorded to equity.
 
In 2014, the Company initially recorded debt discounts of $4,750,000 related to the beneficial conversion feature and related detachable warrants. The beneficial conversion feature discount and the detachable warrants discount are amortized to interest expense over the life of the Notes. The unamortized debt discounts recognized with the Debt Exchange was approximately $679,000. As of March 31, 2019 and December 31, 2018 the remaining balance of the debt discounts is approximately $63,000 and $94,000, respectively. The Company recorded approximately $31,000 and $238,000 amortization of the debt discounts during the three months ended March 31, 2019 and 2018 and is recorded as interest expense.
 
 
 
-31-
 
 
With respect to the 2014 Private Placement, the Company paid approximately $490,000 in expenses including placement agent fees. The issuance costs are amortized to interest expense over the term of the Notes. The unamortized issuance costs recognized with the Debt Exchange was approximately $63,000. As of March 31, 2019 and December 31, 2018 the remaining balance of the issuance costs is approximately $6,000 and $10,000, respectively. The Company recorded approximately $3,000 and $25,000 of the debt discounts amortization during the three months ended March 31, 2019 and 2018, respectively, and is recorded as interest expense.
 
As of March 31, 2019 and December 31, 2018 the principal amount of $750,000 remains outstanding.
 
Unamortized debt discounts and issuance costs are included with convertible notes payable, net of debt discount on the condensed consolidated balance sheets.
 
January 2019 Private Placement
 
On February 15, 2019 and on March 10, 2019, the Company closed its first and second tranches of its 2019 January Private Placement debt offering, respectively, pursuant to which the Company offered for sale a minimum of notes in the principal amount of a minimum of $100,000 and a maximum of notes in the principal amount $10,000,000 (the “2019 PIPE Notes”), with each investor receiving 2,000 shares of common stock for each $100,000 invested. The Company entered into subscription agreements with thirteen (13) accredited investors that had a substantial pre-existing relationship with the Company pursuant to which the Company received aggregate gross proceeds of $2,440,000 and issued 2019 PIPE Notes in the aggregate principal amount of $2,440,000 and an aggregate of 48,800 shares of common stock. The placement agent will receive up to 50,000 shares of common stock in the offering. Each 2019 PIPE Note matures 24 months after issuance, bears interest at a rate of six percent (6%) per annum, and the outstanding principal is convertible into shares of common stock at any time after the 180th day anniversary of the issuance of the 2019 PIPE Note, at a conversion price of $10 per share (subject to adjustment for stock splits, stock dividends and reclassification of the common stock).
 
Upon issuance of the 2019 PIPE Notes, the Company recognized debt discounts of approximately $467,000, resulting from the allocated portion of offering proceeds to the separable common stock issuance. The debt discount is being amortized to interest expense over the term of the 2019 PIPE Notes. During the three months ended March 31, 2019 the Company recorded approximately $7,000 of amortization related to the debt discounts. 
 
Note 9. Derivative Liability
 
The Company recognizes and measures the warrants issued in conjunction with the Company’s August 2018, July 2017, November 2015 and July 2014 Private Placements in accordance with ASC Topic 815, Derivatives and Hedging. The accounting guidance sets forth a two-step model to be applied in determining whether a financial instrument is indexed to an entity’s own stock, which would qualify such financial instruments for a scope exception. This scope exception specifies that a contract that would otherwise meet the definition of a derivative financial instrument would not be considered as such if the contract is both (i) indexed to the entity’s own stock and (ii) classified in the stockholders’ equity section of the entity’s balance sheet. The Company determined that certain warrants and embedded conversion features issued in the Company’s private placements are ineligible for equity classification due to anti-dilution provisions set forth therein.
 
Derivative liabilities are recorded at their estimated fair value (see Note 10, below) at the issuance date and are revalued at each subsequent reporting date. The Company will continue to revalue the derivative liability on each subsequent balance sheet date until the securities to which the derivative liabilities relate are exercised or expire.
 
Various factors are considered in the pricing models the Company uses to value the derivative liabilities, including its current stock price, the remaining life, the volatility of its stock price, and the risk-free interest rate. Future changes in these factors may have a significant impact on the computed fair value of the liability. As such, the Company expects future changes in the fair values to continue and may vary significantly from period to period. The warrant and embedded liability and revaluations have not had a cash impact on working capital, liquidity or business operations.
 
 
 
-32-
 
 
Warrants
 
Effective January 1, 2019, the Company adopted ASU No. 2017-11 (see above, Recently Adopted Accounting Pronouncements). The new guidance requires companies to exclude any down round feature when determining whether a freestanding equity-linked financial instrument (or embedded conversion option) is considered indexed to the entity’s own stock when applying the classification guidance in ASC 815-40. Upon adoption of the new guidance, existing equity-linked financial instruments (or embedded conversion options) with down round features must be reassessed as liability classification may no longer be required. As a result, the Company determined in regard to its 2018 warrants the appropriate treatment of these warrants that were initially classified as derivative liabilities should now be classified as equity instruments.
 
The Company determined that the liability associated with the 2018 warrants should be remeasured and adjusted to fair value on the date of the change in classification with the offset to be recorded through earnings and then the fair value of the warrants should be reclassified to equity. The Company recorded the change in the fair value of the 2018 warrants as of the date of change in classification to earnings. The fair value of the 2018 warrants as of the date of change in classification, in the amount of $1,494,000 was reclassified from warrant derivative liability to additional paid in capital as a result of the change in classification of the warrants.
  
Increases or decreases in the fair value of the derivative liability are included as a component of total other expense in the accompanying condensed consolidated statements of operations for the respective period. The changes to the derivative liability for warrants resulted in a decrease of $1,486,000 and a decrease of $712,000 for the three months ended March 31, 2019 and 2018, respectively.
 
The estimated fair value of the outstanding warrant liabilities is $5,369,000 and $9,216,000 as of March 31, 2019 and December 31, 2018, respectively. 
 
The estimated fair value of the warrants was computed as of March 31, 2019 and December 31, 2018 using the Monte Carlo option pricing model with the following assumptions:
 
 
March 31,
2019
(unaudited)
December 31,
2018
Stock price volatility
97.2% - 111.5%
83.78% - 136.76%
Risk-free interest rates
2.33% - 2.42%
2.465% - 2.577%
Annual dividend yield
0%
0%
Expected life
0.33 - 1.54 years
0.58 - 2.76 years
 
In addition, management assessed the probabilities of future financing assumptions in the valuation models.
  
Note 10.   Fair Value of Financial Instruments
 
Fair value measurements are performed in accordance with the guidance provided by ASC Topic 820, “Fair Value Measurements and Disclosures.” ASC Topic 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or parameters are not available, valuation models are applied.
 
ASC Topic 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities recorded at fair value in the financial statements are categorized based upon the hierarchy of levels of judgment associated with the inputs used to measure their fair value. Hierarchical levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:
  
Level 1 – Quoted prices in active markets for identical assets or liabilities that an entity has the ability to access.
 
Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
 
Level 3 – Unobservable inputs that are supportable by little or no market activity and that are significant to the fair value of the asset or liability.
  
 
 
-33-
 
 
The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, capital lease obligations and deferred revenue approximate their fair values based on their short-term nature. The carrying amount of the Company’s long-term notes payable approximates its fair value based on interest rates available to the Company for similar debt instruments and similar remaining maturities.
 
The estimated fair value of the contingent consideration related to the Company's business combinations is recorded using significant unobservable measures and other fair value inputs and is therefore classified as a Level 3 financial instrument.
 
The following table details the fair value measurement within the fair value hierarchy of the Company’s financial instruments, which includes the Level 3 liabilities (in thousands):
 
 
 
Fair Value at March 31, 2019
 
 
 
Total
 
 
Level 1
 
 
Level 2
 
 
Level 3
 
Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
Contingent acquisition debt, current portion
 $792 
 $- 
 $- 
 $792 
Contingent acquisition debt, less current portion
  7,341 
  - 
  - 
  7,341 
Warrant derivative liability
  5,369 
  - 
  - 
  5,369 
    Total liabilities
 $13,502 
 $- 
 $- 
 $13,502 
 
 
 
Fair Value at December 31,2018
 
 
 
Total
 
 
Level 1
 
 
Level 2
 
 
Level 3
 
Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
Contingent acquisition debt, current portion
 $795 
 $- 
 $- 
 $795 
Contingent acquisition debt, less current portion
  7,466 
  - 
  - 
  7,466 
Warrant derivative liability
  9,216 
  - 
  - 
  9,216 
    Total liabilities
 $17,477 
 $- 
 $- 
 $17,477 
  
The following table reflects the activity for the Company’s warrant derivative liability associated with the Company’s 2019, 2018, 2017, 2015 and 2014 Private Placements measured at fair value using Level 3 inputs (in thousands):
 
 
 
Warrant Derivative Liability
 
Balance at December 31, 2018
 $9,216 
Issuance
  - 
Adjustments to estimated fair value
  (1,486)
Adjustments related to warrant exercises
  (867)
Adjustments related to the reclassification of warrants to equity
  (1,494)
Balance at March 31, 2019
 $5,369 
 
The following table reflects the activity for the Company’s contingent acquisition liabilities measured at fair value using Level 3 inputs (in thousands):
 
 
 
Contingent Consideration
 
Balance at December 31, 2018
 $8,261 
Liabilities acquired
  - 
Liabilities settled
  (128)
Adjustments to liabilities included in earnings
  - 
Adjustment to purchase price
  - 
Balance at March 31, 2019
 $8,133 
 
 
 
-34-
 
 
The fair value of the contingent acquisition liabilities is evaluated each reporting period using projected revenues, discount rates, and projected timing of revenues. Projected contingent payment amounts are discounted back to the current period using a discount rate. Projected revenues are based on the Company’s most recent internal operational budgets and long-range strategic plans. Increases in projected revenues will result in higher fair value measurements. Increases in discount rates and the time to payment will result in lower fair value measurements. Increases (decreases) in any of those inputs in isolation may result in a significantly lower (higher) fair value measurement. During the three months ended March 31, 2018, the net adjustment to the fair value of the contingent acquisition debt was a decrease $213,000 and is included in the Company’s statements of operations in general and administrative expense.  The Company did not have any adjustments to the fair value of the contingent acquisition debt during the three months ended March 31, 2019.
   
Note 11.  Stockholders’ Equity
 
The Company’s Certificate of Incorporation, as amended, authorizes the issuance of two classes of stock to be designated: “Common Stock” and “Preferred Stock”.
 
The total number of shares of stock which the Company has authority to issue is 50,000,000 shares of common stock, par value $0.001 per share and 5,000,000 shares of preferred stock, par value $0.001 per share, of which 161,135 shares have been designated as Series A convertible preferred stock, par value $0.001 per share (“Series A Convertible Preferred”), 1,052,631 has been designated as Series B convertible preferred stock (“Series B Convertible Preferred”), and 700,000 has been designated as Series C convertible preferred stock (“Series C Convertible Preferred”).
 
Common Stock
 
As of March 31, 2019 and December 31, 2018 there were 28,890,671 and 25,760,708 shares of common stock outstanding, respectively. The holders of the common stock are entitled to one vote for each share held at all meetings of stockholders (and written actions in lieu of meetings).  
 
Stock Offering
 
On February 6, 2019, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with one accredited investor that had a substantial pre-existing relationship with the Company pursuant to which the Company sold 250,000 shares of common stock, par value $0.001 per share, at an offering price of $7.00 per share. Pursuant to the Purchase Agreement, the Company also issued to the investor a three-year warrant to purchase 250,000 shares of common stock at an exercise price of $7.00. The proceeds were $1,750,000. Consulting fees for arranging the Purchase Agreement include the issuance of 5,000 shares of restricted shares of the Company’s common stock, par value $0.001 per share, and 100,000 3-year warrants priced at $10.00. No cash commissions were paid.
 
On February 15, 2019 and on March 10, 2019, the Company closed its first and second tranches of its 2019 January Private Placement debt offering, respectively, pursuant to which the Company offered for sale a minimum of notes in the principal amount of a minimum of $100,000 and a maximum of notes in the principal amount $10,000,000 (the “2019 PIPE Notes”), with each investor receiving 2,000 shares of common stock for each $100,000 invested. The Company entered into subscription agreements with thirteen (13) accredited investors that had a substantial pre-existing relationship with the Company pursuant to which the Company received aggregate gross proceeds of $2,440,000 and issued 2019 PIPE Notes in the aggregate principal amount of $2,440,000 and an aggregate of 48,800 shares of common stock. The placement agent will receive up to 50,000 shares of common stock in the offering. Each 2019 PIPE Note matures 24 months after issuance, bears interest at a rate of six percent (6%) per annum, and the outstanding principal is convertible into shares of common stock at any time after the 180th day anniversary of the issuance of the 2019 PIPE Note, at a conversion price of $10 per share (subject to adjustment for stock splits, stock dividends and reclassification of the common stock).
 
 
 
-35-
 
 
On March 18, 2019, the Company entered into a two-year Secured Promissory Note (the “Note or Notes”) with two accredited investors that the Company had a substantial pre-existing relationship with and from whom the Company raised cash proceeds in the aggregate of $2,000,000. In consideration of the Notes, the Company issued 20,000 shares of common stock par value $0.001 for each $1,000,000 invested as well as for each $1,000,000 invested and five-year warrants to purchase 20,000 shares of common stock at a price per share of $6.00. The Notes pay interest at a rate of eight percent (8%) per annum and interest is paid quarterly in arrears with all principal and unpaid interest due at maturity on March 18, 2021. The Company issued 40,000 shares of common stock and 40,000 warrants with the Notes.
 
Issuance of additional common shares and repricing of warrants related to 2018 Private Placement
 
On March 13, 2019, the Company determined that three of the investors of the Company’s August 2018 Private Placement became eligible to receive additional shares of the Company’s common stock as it was referred to in their respective Purchase Agreement as True-up Shares. Total number of additional shares issued to those three investors is 44,599 shares of restricted shares of the Company’s common stock, par value $0.001. In addition, the exercise price of the warrants issued at their respective closings is reset pursuant to the terms of the warrants to exercise prices ranging from $4.06 to $4.44 from the exercise price at issuance of $4.75.
 
Convertible Preferred Stock
 
Series A Convertible Preferred Stock
 
The Company has 161,135 shares of Series A Convertible Preferred Stock outstanding as of March 31, 2019, and December 31, 2018 and accrued dividends of approximately $140,000 and $137,000, respectively. The holders of the Series A Convertible Preferred Stock are entitled to receive a cumulative dividend at a rate of 8.0% per year, payable annually either in cash or shares of the Company's common stock at the Company's election. Each share of Series A Convertible Preferred is convertible into common stock at a conversion rate of 0.10. The holders of Series A Convertible Preferred are entitled to receive payments upon liquidation, dissolution or winding up of the Company before any amount is paid to the holders of common stock. The holders of Series A Convertible Preferred have no voting rights, except as required by law.  
 
Series B Convertible Preferred Stock
 
On March 30, 2018, the Company completed the Series B Offering, pursuant to which the Company sold 381,173 shares of Series B Convertible Preferred Stock at an offering price of $9.50 per share and received gross proceeds in aggregate of approximately $3,621,000. The net proceeds to the Company from the Series B Offering were approximately $3,289,000 after deducting commissions, closing and issuance costs. Each share of Series B Convertible Preferred Stock is initially convertible at any time, in whole or in part, at the option of the holders, at an initial conversion price of $4.75 per share, into two (2) shares of common stock and automatically converts into two (2) shares of common stock on its two-year anniversary of issuance.
 
The Company has 129,437 shares of Series B Convertible Preferred Stock outstanding as of March 31, 2019 and December 31, 2018. The holders of the Series B Convertible Preferred Stock are entitled to receive cumulative dividends on the Series B Convertible Preferred Stock from the date of original issue at a rate of 5.0% per annum payable quarterly in arrears on or about the last day of March, June, September and December of each year, beginning June 30, 2018. As of March 31, 2019 and December 31, 2018 accrued dividends were approximately $11,000 and $11,000, respectively.
 
The shares of Series B Convertible Preferred Stock issued in the Series B Offering were sold pursuant to the Company’s Registration Statement, which was declared effective on February 13, 2018. Upon the receipt of the proceeds of the Series B Offering, the 2017 Notes in the principal amount of approximately $7,254,000 automatically converted into 1,577,033 shares of common stock. The holders of Series B Convertible Preferred are entitled to receive a distribution, to be paid in an amount equal to $9.50 for each and every share of Series B Preferred Stock held by the holders of Series B Preferred Stock, plus all accrued and unpaid dividends in preference to any distribution or payments made or any asset distributed to the holders of common stock, the Series A Preferred Stock, or any other class or series of stock ranking junior to the Series B Preferred Stock. Holders of the Series B Convertible Preferred Stock have no voting rights, except as required by law.
 
 
 
-36-
 
 
Series C Preferred Stock
 
Between August 17, 2018 and October 4, 2018, the Company closed three tranches of its Series C Offering, pursuant to which the Company sold 697,363 shares of Series C Convertible Preferred Stock at an offering price of $9.50 per share and agreed to issue two-year warrants (the “Preferred Warrants”) to purchase up to 1,394,726 shares of the Company’s common stock at an exercise price of $4.75 per share to Series C Preferred holders that voluntarily convert their shares of Series C Preferred to the Company’s common stock within two-years from the issuance date. Each share of Series C Convertible Preferred Stock is initially convertible at any time, in whole or in part, at the option of the holders, at an initial conversion price of $4.75 per share, into two (2) shares of common stock and automatically converts into two (2) shares of common stock on its two-year anniversary of issuance.
 
The Company issued the placement agent in connection with the Series C Offering 116,867 warrants as compensation, exercisable at $4.75 per share and expire in December 2020. The Company determined that the warrants should be classified as equity instruments and used Black-Scholes to estimate the fair value of the warrants issued to the placement agent of $458,000 as of the issuance date December 19, 2018. As of December 31, 2018, the 116,867 warrants issued to the placement agent remain outstanding.
 
The Company received aggregate gross proceeds totaling approximately $6,625,000. The net proceeds to the Company from the Series C Offering were approximately $6,236,000 after deducting commissions, closing and issuance costs.
 
Upon liquidation, dissolution or winding up of the Company, each holder of Series C Preferred Stock was entitled to receive a distribution, to be paid in an amount equal to $9.50 for each and every share of Series C Preferred Stock held by the holders of Series C Preferred Stock, plus all accrued and unpaid dividends in preference to any distribution or payments made or any asset distributed to the holders of common stock, the Series A Preferred Stock, the Series B Preferred Stock or any other class or series of stock ranking junior to the Series C Preferred Stock.
 
The shares of Series C Convertible Preferred Stock issued in the Series C Offering were sold pursuant to the Company’s Registration Statement, which was declared effective with the SEC on December 10, 2018.
 
Pursuant to the Certificate of Designation, the Company agreed to pay cumulative dividends on the Series C Convertible Preferred Stock from the date of original issue at a rate of 6.0% per annum payable quarterly in arrears on or about the last day of March, June, September and December of each year, beginning September 30, 2018. In 2018 a total of approximately $51,000 of dividends was paid to the holders of the Series C Convertible Preferred Stock. The Series C Convertible Preferred Stock ranks senior to the Company’s outstanding Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and the common stock with respect to dividend rights and rights upon liquidation, dissolution or winding up. Holders of the Series C Convertible Preferred Stock have no voting rights.
 
The contingent obligation to issue warrants is considered an outstanding equity-linked financial instrument and was therefore recognized as equity classified warrants, initially measured at relative fair value of approximately $3,727,000, resulting in an initial discount to the carrying value of the Series C Preferred Stock.
 
Due to the reduction of allocated proceeds to the contingently issuable common stock warrants and Series C Preferred Stock, the effective conversion price of the Series C Preferred Stock was less than the Company’s common stock price on each commitment date, resulting in an aggregate beneficial conversion feature of approximately $3,276,000, which reduced the carrying value of the Series C Preferred Stock. Since the conversion option of the Series C Preferred Stock was immediately exercisable, the beneficial conversion feature was immediately accreted as a deemed dividend, resulting in an increase in the carrying value of the C Preferred Stock of approximately $3,276,000.
 
The Series C Preferred Stock was automatically redeemable at a price equal to its original purchase price plus all accrued but unpaid dividends in the event the average of the daily volume weighted average price of the Company’s common stock for the 30 days preceding the two-year anniversary date of issuance is less than $6.00 per share.  As redemption was outside of the Company’s control, the Series C Preferred Stock was classified in temporary equity at issuance. All of the Series C Preferred shares were converted to common stock during 2018 and the Company has issued 1,394,726 warrants. As of March 31, 2019, no shares of Series C Convertible Preferred Stock remain outstanding.
 
 
 
-37-
 
 
Repurchase of Common Stock
 
On December 11, 2012, the Company authorized a share repurchase program to repurchase up to 750,000 of the Company's issued and outstanding shares of common stock from time to time on the open market or via private transactions through block trades.  A total of 196,594 shares have been repurchased to-date as of March 31, 2019 at a weighted-average cost of $5.30 per share. There were no repurchases during the three months ended March 31, 2019 and 2018. The remaining number of shares authorized for repurchase under the plan as of March 31, 2019 is 553,406.
 
Advisory Agreements
 
The Company records the fair value of common stock issued in conjunction with advisory service agreements based on the closing stock price of the Company’s common stock on the measurement date. The fair value of the stock issued is recorded through equity and prepaid advisory fees and amortized over the life of the service agreement.
 
ProActive Capital Resources Group, LLC
 
On September 1, 2015, the Company entered into an agreement with ProActive Capital Resources Group, LLC (“PCG”), pursuant to which PCG agreed to provide investor relations services for six (6) months in exchange for fees paid in cash of $6,000 per month and 5,000 shares of restricted common stock to be issued upon successfully meeting certain criteria in accordance with the agreement. Subsequent to the September 1, 2015 initial agreement, the agreement was extended through August 2018 under six-month incremental service agreements under the same terms with the monthly cash payments of $6,000 per month and 5,000 shares of restricted common stock for every six (6) months of service performed.
 
The stock issuance expense associated with the amortization of advisory fees is recorded as stock issuance expense and is included in general and administrative expense on the Company’s condensed consolidated statements of operations for the three months ended March 31, 2018 is approximately $13,000. The Company did not further extend this agreement subsequent to August 2018.
 
Ignition Capital, LLC
 
On April 1, 2018, the Company entered into an agreement with Ignition Capital, LLC (“Ignition”), pursuant to which Ignition agreed to provide investor relations services for a period of twenty-one (21) months in exchange for 50,000 shares of restricted common stock which were issued in advance of the service period. The fair value of the shares issued is recorded as prepaid advisory fees and is included in prepaid expenses and other current assets on the Company’s condensed consolidated balance sheets and is amortized on a pro-rata basis over the term of the agreement. During the three months ended March 31, 2019, the Company recorded expense of approximately $30,000 in connection with amortization of the stock issuance. The stock issuance expense associated with the amortization of advisory fees is recorded as stock issuance expense and is included in general and administrative expense on the Company’s condensed consolidated statements of operations for the three months ended March 31, 2019.

Greentree Financial Group, Inc.
 
On March 27, 2018, the Company entered into an agreement with Greentree Financial Group, Inc. (“Greentree”), pursuant to which Greentree agreed to provide investor relations services for a period of twenty-one (21) months in exchange for 75,000 shares of restricted common stock which were issued in advance of the service period. The fair value of the shares issued is approximately $311,000 and is recorded as prepaid advisory fees and is included in prepaid expenses and other current assets on the Company’s condensed consolidated balance sheets and is amortized on a pro-rata basis over the term of the agreement. During the three months ended March 31, 2018, the Company recorded expense of approximately $44,000 in connection with amortization of the stock issuance. The stock issuance expense associated with the amortization of advisory fees is recorded as stock issuance expense and is included in general and administrative expense on the Company’s condensed consolidated statements of operations for the three months ended March 31, 2019.
 
 
-38-
 
 
Capital Market Solutions, LLC.
 
On July 1, 2018, the Company entered into an agreement with Capital Market Solutions, LLC. (“Capital Market”), pursuant to which Capital Market agreed to provide investor relations services for a period of 18 months in exchange for 100,000 shares of restricted common stock which were issued in advance of the service period. In addition, the Company agreed to pay in cash a base fee of $300,000, payable as follows; $50,000 paid in August 2018, and the remaining balance shall be paid monthly in the amount of $25,000 through January 1, 2019. Subsequent to the initial agreement, the Company extended the term for an additional 24 months through December 31, 2021 and agreed to issue Capital Market an additional 100,000 shares of restricted common stock which were issued in advance of the service period and $125,000 of additional fees. On January 9, 2019, the Company executed the second amendment to the agreement with Capital Market, pursuant to which, the aggregate base fee increased to $525,000, and the Company issued an additional 75,000 of restricted common stock. In addition, the Company issued to Capital Market a four-year warrant to purchase 925,000 shares of the Company’s common stock at $6.00 per share vesting 50% at issuance on January 9, 2019 and 25% on January 9, 2020 and 25% on January 9, 2021. The fair value of the vested portion of the warrant is approximately $1,656,000 and is recorded as equity on the Company’s balance sheet as of March 31, 2019 and equity issuance expense on the Company’s condensed consolidated statement of operations for the three months ended March 31, 2019.
 
The fair value of the common stock shares issued is recorded as prepaid advisory fees and is included in prepaid expenses and other current assets on the Company’s condensed consolidated balance sheets and is amortized on a pro-rata basis over the term of the agreement. During the three months ended March 31, 2019 and 2018, the Company recorded expense of approximately $129,000, in connection with amortization of the stock issuance expense. During the three months ended March 31, 2019, the Company recorded expense of approximately $50,000, in connection with the base fee. The stock issuance expense associated with the amortization of advisory fees is recorded as stock issuance expense and is included in general and administrative expense on the Company’s condensed consolidated statements of operations for the three months ended March 31, 2019.
 
Warrants
 
As of March 31, 2019, warrants to purchase 6,943,874 shares of the Company's common stock at prices ranging from $2.00 to $10.00 were outstanding. As of March 31, 2019, 6,539,187 warrants are exercisable and expire at various dates through March 2024 and have a weighted average remaining term of approximately 2.23 years and are included in the table below as of March 31, 2019.
 
The Company uses the Monte Carlo and Black-Scholes option-pricing model to estimate the fair value of the warrants. 
 
Warrants – Securities Purchase Agreement
 
During the three months ended March 31, 2019, the Company issued the selling agent in connection with the Securities Purchase Agreement 100,000 warrants as compensation, exercisable at $10.00 per share and expire in February 2022. The Company used the Black-Scholes option-pricing model (“Black-Scholes”) to estimate the fair value of the warrants issued to the selling agent of $324,000 as of March 30, 2019. 
 
A summary of the warrant activity for the three months ended March 31, 2019 is presented in the following table:
 
 
 
Number of
Warrants
 
Balance at December 31, 2018
  5,876,980 
    Issued
  1,315,000 
    Expired / cancelled
  - 
    Exercised
  (248,106)
Balance at March 31, 2019, outstanding
  6,943,874 
Balance at March 31, 2019, exercisable
  6,539,187 
 
 
 
-39-
 
 
Stock Options
 
On May 16, 2012, the Company established the 2012 Stock Option Plan (“Plan”) authorizing the granting of options for up to 9,000,000 shares of common stock.
 
The purpose of the Plan is to promote the long-term growth and profitability of the Company by (i) providing key people and consultants with incentives to improve stockholder value and to contribute to the growth and financial success of the Company and (ii) enabling the Company to attract, retain and reward the best available persons for positions of substantial responsibility. The Plan allows for the grant of: (a) incentive stock options; (b) nonqualified stock options; (c) stock appreciation rights; (d) restricted stock; and (e) other stock-based and cash-based awards to eligible individuals qualifying under Section 422 of the Internal Revenue Code, in any combination (collectively, “Options”). At March 31, 2019, the Company had 3,587,072 shares of common stock available for issuance under the Plan. 
 
A summary of the Plan stock option activity for the three months ended March 31, 2019 is presented in the following table: 
 
 
 
 
Number of
Shares
 
 
 
Weighted Average
Exercise Price
 
 
Weighted Average
Remaining Contract Life (years)
 
 
Aggregate Intrinsic Value (in thousands)
 
Outstanding December 31, 2018
  2,394,379 
 $4.45 
  6.94 
 $3,049 
Issued
  2,540,000 
  6.66 
    
    
Canceled / expired
  (37,275)
  5.00 
    
    
Exercised
  (60,530)
  4.46 
    
  - 
Outstanding March 31, 2019
  4,836,574 
 $5.61 
  8.35 
 $3,045 
Exercisable March 31, 2019
  3,723,870 
 $5.96 
  8.23 
 $1,617 
 
The weighted-average fair value per share of the granted options for the three months ended March 31, 2019 was approximately $4.26. There were no options granted during the three months ended March 31, 2018
 
Stock-based compensation expense included in the condensed consolidated statements of operations was $11,248,000 and $122,000 for the three months ended March 31, 2019 and 2018, respectively.
 
As of March 31, 2019, there was approximately $2,132,000 of total unrecognized compensation expense related to unvested stock options granted under the Plan. The expense is expected to be recognized over a weighted-average period of 1.75 years.
 
The Company uses the Black-Scholes to estimate the fair value of stock options. The use of a valuation model requires the Company to make certain assumptions with respect to selected model inputs. Expected volatility is calculated based on the historical volatility of the Company’s stock price over the expected term of the option. The expected life is based on the contractual life of the option and expected employee exercise and post-vesting employment termination behavior. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term equal to the expected life assumed at the date of the grant. 
 
Restricted Stock Units
 
On August 9, 2017, the Company issued restricted stock units for an aggregate of 500,000 shares of common stock, to its employees and consultants. These shares of common stock will be issued upon vesting of the restricted stock units. Full vesting occurs on the sixth-year anniversary of the grant date, with 10% vesting on the third-year, 15% on the fourth-year, 50% on the fifth-year and 25% on the sixth-year anniversary of the vesting commencement date. As of March 31, 2019, none of the restricted stock units have vested. There were no grants during the three months ended March 31, 2019.
 
 
-40-
 
 
The fair value of each restricted stock unit issued to employees is based on the closing stock price on the grant date of $4.53 and restricted stock units issued to consultants are revalued as they vest and is recognized as stock-based compensation expense over the vesting term of the award.
 
 
 
Number of
Shares
 
Balance at December 31, 2018
  475,000 
    Issued
  - 
    Canceled
  - 
Balance at March 31, 2019
  475,000 
 
Stock-based compensation expense included in the condensed consolidated statements of operations was $96,000 and $115,000 for the three months ended March 31, 2019 and 2018, respectively.
 
As of March 31, 2019, total unrecognized stock-based compensation expense related to restricted stock units to employees and consultants was approximately $1,629,000, which will be recognized over a weighted average period of 4.36 years.
 
Note 12.  Segment and Geographical Information
 
The Company is a leading multi-channel lifestyle company offering a hybrid of the direct selling business model that also offers e-commerce and the power of social selling. Assembling a virtual main street of products and services under one corporate entity, Youngevity offers products from top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. The Company operates in three segments: the direct selling segment where products are offered through a global distribution network of preferred customers and distributors, the commercial coffee segment where roasted and green coffee bean products are sold directly to businesses, and commercial hemp segment provides end to end extraction and processing via the Company's proprietary systems that allow for the conversion of hemp feed stock into hemp oil and hemp extracts.  The primary focus of the segment will be to generate revenue through sales of extraction services and end to end processing services for the conversion of Hemp and Hemp oil into sellable ingredients.  Additionally, the Company offers various rental, sales, and service programs of the company's extraction and processing systems.
 
The Company’s segments reflect the manner in which the business is managed and how the Company allocates resources and assesses performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company’s chief operating decision maker evaluates segment performance primarily based on revenue and segment operating income. The principal measures and factors the Company considered in determining the number of reportable segments were revenue, gross margin percentage, sales channel, customer type and competitive risks.
 
The accounting policies of the segments are consistent with those described in the summary of significant accounting policies. Segment revenue excludes intercompany revenue eliminated in the consolidation. The following tables present certain financial information for each segment (in thousands):
 
 
 
-41-
 
 
 
 
Three Months Ended
March 31,
 
 
 
2019
(unaudited)
 
 
2018
 
Revenues
 
(Restated)*
 
 
 
 
   Direct selling
 $33,420 
 $35,311 
   Commercial coffee
  7,705 
  7,683 
   Commercial hemp
  67 
  - 
      Total revenues
 $41,192 
 $42,994 
Gross profit
    
    
   Direct selling
 $22,755 
 $24,735 
   Commercial coffee
  4,067 
  277 
   Commercial hemp
  27 
  - 
      Total gross profit
 $26,849 
 $25,012 
Operating income (loss)
    
  - 
   Direct selling
 $(12,309)
 $781 
   Commercial coffee
  884 
  (757)
   Commercial hemp
  (516)
  - 
      Total operating income (loss)
 $(11,941)
 $24 
Net income (loss)
    
    
   Direct selling
 $(13,377)
 $(591)
   Commercial coffee
  1,633 
  (1,717)
   Commercial hemp
  (516)
  - 
      Total net loss  
 $(12,260)
 $(2,308)
Capital expenditures
    
    
   Direct selling
 $17 
 $87 
   Commercial coffee
  2,572 
  679 
   Commercial hemp
  1,384 
  - 
      Total capital expenditures
 $3,973 
 $766 
Capital expenditures acquired through acquisition


    Direct selling
 $- 
 $- 
    Commercial coffee
  - 
  - 
    Commercial hemp
  1,133 
  - 
        Total capital expenditures acquired through acquisition  
 $1,133 
 $- 
 
 
 
As of
 
 
 
March 31,
2019
(unaudited)
 
 
December 31,
2018
 
Total assets
 
 (Restated)*
 
 
 
 
   Direct selling
 $45,011 
 $38,947 
   Commercial coffee
  41,584 
  37,026 
   Commercial hemp
  21,189 
  - 
      Total assets
 107,784 
 $75,973 
 
* Segment results and total assets as of and for the three months ended March 31, 2019 have been restated. See Note 2.
 
Total tangible assets, net located outside the United States were approximately $7.3 million and $6.2 million as of March 31, 2019 and December 31, 2018, respectively.
 
The Company conducts its operations primarily in the United States. For both the three months ended March 31, 2019 and 2018 approximately 13% of the Company’s sales were derived from sales outside the United States.
 
The following table displays revenues attributable to the geographic location of the customer (in thousands):
 
 
 
Three Months
Ended March 31,
 
 
 
2019
(unaudited)
 
 
2018
 
Revenues
 
(Restated)*
 
 
 
 
   United States
 $35,782 
 $37,393 
   International
  5,410 
  5,601 
      Total revenues
 $41,192 
 $42,994 
 
* Revenue for the three months ended March 31, 2019 has been restated. See Note 2.
 
 
 
-42-
 
 
Note 13.  Subsequent Events
 
None.
 
 
 
-43-
 
 
ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
Restatement of previously reported unaudited condensed consolidated financial statements
 
This “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” has been amended and restated to give effect to the restatement of our unaudited condensed consolidated financial statements as more fully described in “Note 2. Restatement of previously reported unaudited condensed consolidated financial statements” in “Item 1. Financial Statements.”
 
FORWARD LOOKING STATEMENTS
 
This quarterly report on Form 10-Q/A contains forward-looking statements. The words “expects,” “anticipates,” “believes,” “intends,” “plans” and similar expressions identify forward-looking statements. In addition, any statements which refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. We undertake no obligation to publicly disclose any revisions to these forward-looking statements to reflect events or circumstances occurring subsequent to filing this Form 10-Q/A with the Securities and Exchange Commission. These forward-looking statements are subject to risks and uncertainties, including, without limitation, those risks and uncertainties discussed in Part I, Item 1A, “Risk Factors” and in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our annual report on Form 10-K filed with the Securities and Exchange Commission on April 15, 2019 and herein as reported under Part II Other Information, Item 1A. Risk Factors. In addition, new risks emerge from time to time and it is not possible for management to predict all such risk factors or to assess the impact of such risk factors on our business. Accordingly, our future results may differ materially from historical results or from those discussed or implied by these forward-looking statements. Given these risks and uncertainties, the reader should not place undue reliance on these forward-looking statements.
 
In the following text, the terms “we,” “our,” and “us” may refer, as the context requires, to Youngevity International, Inc. or collectively to Youngevity International, Inc. and its subsidiaries.
  
Overview
 
We operate in three segments: (i) the direct selling segment, where products are offered through a global distribution network of preferred customers and distributors, (ii) the commercial coffee segment, where products are sold directly to businesses, processed green coffee beans are processed and milling services are provided for unprocessed green coffee beans, and (iii) the commercial hemp segment, where we manufacture proprietary systems to provide end-to-end extraction and processing that allow for the conversion of hemp feed stock into hemp oil and hemp extracts.
 
In the direct selling segment, we sell health and wellness products on a global basis and offer a wide range of products through an international direct selling network of independent distributors. Our multiple independent selling forces sell a variety of products through friend-to-friend marketing and social networking.  
 
We also engage in the commercial sale of coffee. We own a traditional coffee roasting business, CLR, that sells roasted and unroasted coffee and produces coffee under its own Café La Rica brand, Josie’s Java House brand and Javalution brands. CLR produces coffee under a variety of private labels through major national sales outlets and major customers including cruise lines and office coffee service operators. During fiscal 2014 CLR acquired the Siles Plantation Family Group, a coffee plantation and dry-processing facility located in Matagalpa, Nicaragua, an ideal coffee growing region that is historically known for high quality coffee production. The dry-processing facility is approximately 26 acres and the plantation is approximately 500 acres and produces 100 percent Arabica coffee beans that are shade grown, Rainforest Alliance Certified™ and Fair Trade Certified™. CLR is also in the process of expanding its capabilities in Nicaragua by constructing a large processing mill. The plantation, the dry-processing facilities and existing U.S. based coffee roaster facilities allows CLR to control the coffee production process from field to cup.
 
In the commercial hemp segment, we are engaged in the CBD hemp extraction technology and equipment business. We develop, manufacture and sell equipment and related services to clients which enable them to extract CBD oils from hemp stock.
 
We conduct our operations primarily in the United States. For both the three months ended March 31, 2019 and 2018, approximately 87% of our revenues were derived from sales within the United States.
 
 
 
-44-
 
 
Recent Events
 
New Acquisitions During the three months ended March 31, 2019
 
New Acquisitions - Khrysos Global, Inc.
(See Note 2 and Note 5, to the condensed consolidated financial statements)
 
On February 12, 2019, we and Khrysos Industries, Inc., a Delaware corporation our wholly owned subsidiary of (“KII”) entered into an Asset and Equity Purchase Agreement (the “AEPA”) with, Khrysos Global, Inc., a Florida corporation (“Seller”), Leigh Dundore (“LD”), and Dwayne Dundore (the “Representing Party”) for KII to acquire substantially all the assets (the “Assets”) of KGI and all the outstanding equity of INXL Laboratories, Inc., a Florida corporation (“INXL”) and INX Holdings, Inc., a Florida corporation (“INXH”). Seller, INXL and INXH provides end to end extraction and processing via the company's proprietary systems that allow for the conversion of hemp feed stock into hemp oil and hemp extracts.  Additionally, the company offers various rental, sales, and service programs of the company’s extraction and processing systems.
 
The consideration payable for the assets and the equity of KGI, INXL and INXH is an aggregate of $16,000,000, to be paid as set forth under the terms of the AEPA and allocated between the Sellers and LD in such manner as they determine at their discretion.
 
At closing, Seller, LD and the Representing Party received an aggregate of 1,794,972 shares of our common stock which have a value of $14,000,000 for the purposes of the AEPA or $12,649,000 fair value for the acquisition valuation and $500,000 in cash. Thereafter, Seller, LD and the Representing Party are to receive an aggregate of: $500,000 in cash thirty (30) days following the date of closing; $250,000 in cash ninety (90) days following the date of closing; $250,000 in cash one hundred and eighty (180) days following the Date of closing; $250,000 in cash two hundred and seventy (270) days following the date of closing; and $250,000 in cash one (1) year following the date of closing.
 
In addition, we agreed to issue to Representing Party, subject to the approval of the holders of at least a majority of the issued and outstanding shares of our common stock and the approval of The Nasdaq Stock Market (collectively, the “Contingent Consideration Warrants”) consisting of six (6) six-year warrants, to purchase 500,000 shares of common stock each, for an aggregate of 3,000,000 shares of common stock at an exercise price of $10 per share exercisable upon reaching certain levels of cumulative revenue or cumulative net income before taxes by the business during the any of the years ending December 31, 2019, 2020, 2021, 2022, 2023 or 2024.

The AEPA contains customary representations, warranties and covenants of Youngevity, KII, the Seller, LD and the Representing Party. Subject to certain customary limitations, the Seller, LD and the Representing Party have agreed to indemnify us and KII against certain losses related to, among other things, breaches of the Seller’s, LD’s and the Representing Party’s representations and warranties, certain specified liabilities and the failure to perform covenants or obligations under the AEPA.
 
On February 28, 2019, KII purchased a 45-acre tract of land in Groveland, Florida, in central Florida, which KII intends to build R&D facility, greenhouse and allocate a portion for farming.
 
Overview of Significant Events
 
At-the-Market Equity Offering Program
 
On January 7, 2019, we entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with The Benchmark Company, LLC (“Benchmark”), as sales agent, pursuant to which we may sell from time to time, at its option, shares of our common stock, par value $0.001 per share, through Benchmark, as sales agent (the “Sales Agent”), for the sale of up to $60,000,000 of shares of our common stock. We are not obligated to make any sales of common stock under the ATM Agreement and we cannot provide any assurances that it will issue any shares pursuant to the ATM Agreement. We will pay the Sales Agent 3.0% commission of the gross sales proceeds. During the three months ended March 31, 2019, the Company sold a total of 1,000 shares of common stock under the ATM Agreement for an aggregate purchase price of $6.6118 pursuant to the ATM Agreement.
 
 
 
-45-
 
 
Cross-Marketing Agreement
 
On January 10, 2019, we entered into an exclusive cross-marketing agreement with Icelandic Glacial™ an Iceland based spring water drinking water company and is now available for customers to purchase.
 
Mill Construction Agreement
  
On January 15, 2019, CLR entered into the CLR Siles Mill Construction Agreement (the “Mill Construction Agreement”) with H&H and H&H Export, Alain Piedra Hernandez (“Hernandez”) and Marisol Del Carmen Siles Orozco (“Orozco”), together with H&H, H&H Export, Hernandez and Orozco, collectively referred to as the Nicaraguan Partner, pursuant to which the Nicaraguan Partner agreed to transfer a 45 acre tract of land in Matagalpa, Nicaragua (the “Property”) to be owned 50% by the Nicaraguan Partner and 50% by CLR. In consideration for the land acquisition the Company issued to H&H Export, 153,846 shares of common stock. In addition, the Nicaraguan Partner and CLR agreed to contribute $4,700,000 each toward construction of a processing plant, office, and storage facilities (“Mill”) on the property for processing coffee in Nicaragua. As of March 31, 2019, the Company has made deposits of $2,250,000 towards the Mill, which is included in construction in process in property and equipment, net on the Company’s consolidated balance sheet.
  
Amendment to Operating and Profit-Sharing Agreement
 
On January 15, 2019, CLR entered into an amendment to the March 2014 operating and profit-sharing agreement with the owners of H&H. CLR engaged Hernandez and Orozco, the owners of H&H as employees to manage Siles. In addition, CLR and H&H, Hernandez and Orozco have agreed to restructure their profit-sharing agreement in regard to profits from green coffee sales and processing that increases the CLR’s profit participation by an additional 25%. Under the new terms of the agreement with respect to profit generated from green coffee sales and processing from La Pita, a leased mill, or the new mill, now will provide for a split of profits of 75% to CLR and 25% to the Nicaraguan Partner, after certain conditions are met. We issued 295,910 shares of our common stock to H&H Export to pay for certain working capital, construction and other payables. In addition, H&H Export has sold to CLR its espresso brand Café Cachita in consideration of the issuance of 100,000 shares of our common stock. Hernandez and Orozco are employees of CLR. The shares of common stock issued were valued at $7.50 per share.
 
Stock Offering
 
On February 6, 2019, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with one accredited investor that had a substantial pre-existing relationship with us pursuant to which we sold 250,000 shares of our common stock, par value $0.001 per share, at an offering price of $7.00 per share. Pursuant to the Purchase Agreement, we also issued to the investor a three-year warrant to purchase 250,000 shares of common stock at an exercise price of $7.00. The proceeds to us were $1,750,000. Consulting fees for arranging the Purchase Agreement include the issuance of 5,000 shares of restricted shares of our common stock, par value $0.001 per share, and 100,000 3-year warrants priced at $10.00. No cash commissions were paid.
 
Convertible Notes
 
On February 15, 2019 and on March 10, 2019, the Company closed its first and second tranches of its 2019 January Private Placement debt offering, respectively, pursuant to which the Company offered for sale a minimum of notes in the principal amount of a minimum of $100,000 and a maximum of notes in the principal amount $10,000,000 (the “2019 PIPE Notes”), with each investor receiving 2,000 shares of common stock for each $100,000 invested. The Company entered into subscription agreements with thirteen (13) accredited investors that had a substantial pre-existing relationship with the Company pursuant to which the Company received aggregate gross proceeds of $2,440,000 and issued 2019 PIPE Notes in the aggregate principal amount of $2,440,000 and an aggregate of 48,800 shares of common stock. The placement agent will receive up to 50,000 shares of common stock in the offering. Each 2019 PIPE Note matures 24 months after issuance, bears interest at a rate of six percent (6%) per annum, and the outstanding principal is convertible into shares of common stock at any time after the 180th day anniversary of the issuance of the 2019 PIPE Note, at a conversion price of $10 per share (subject to adjustment for stock splits, stock dividends and reclassification of the common stock).
 
 
 
-46-
 
 
Promissory Notes
 
On March 18, 2019, we entered into a two-year Secured Promissory Note (the “Note or Notes”) with two accredited investors that we had a substantial pre-existing relationship with and from whom we raised cash proceeds in the aggregate of $2,000,000. In consideration of the Notes, we issued 20,000 shares of our common stock par value $0.001 for each $1,000,000 invested as well as for each $1,000,000 invested and five-year warrants to purchase 20,000 shares of our common stock at a price per share of $6.00. The Notes pay interest at a rate of eight percent (8%) per annum and interest is paid quarterly in arrears with all principal and unpaid interest due at maturity on March 18, 2021.
 
Results of Operations
 
Three months ended March 31, 2019 compared to three months ended March 31, 2018
 
Revenues
 
For the three months ended March 31, 2019, our revenues decreased 4.2% to $41,192,000 as compared to $42,994,000 for the three months ended March 31, 2018. During the three months ended March 31, 2019, we derived approximately 81.1% of our revenue from our direct selling segment, 18.7% of our revenue from our commercial coffee segment and 0.2% of our revenue from our commercial hemp segment. 
 
For the three months ended March 31, 2019, direct selling segment revenues decreased by $1,891,000 or 5.4% to $33,420,000 as compared to $35,311,000 for the three months ended March 31, 2018. This decrease was primarily attributed to revenues from new acquisitions of $421,000, offset by a decrease of $2,333,000 in revenues from existing business. The decrease in direct selling revenues was also attributable to a general decline in net sales, primarily in North America and in Taiwan.
 
For the three months ended March 31, 2019, commercial coffee segment revenues increased by $22,000 or 0.3% to $7,705,000 as compared to $7,683,000 for the three months ended March 31, 2018. This increase was primarily attributed to increased revenues of $81,000 from our roasted coffee business, offset by a decrease in revenues from sales of green coffee of $4,885,000, attributable to the change in recognition of H&H Export revenue in 2019 to milling and processing services related to the green coffee business. The decrease in sales from green coffee was offset by revenues from milling and processing services of approximately $4,826,000 to H&H Export.
 
Our new commercial hemp segment recorded $67,000 in revenues related to the acquisition of Khrysos which closed on February 15, 2019.
 
The following table summarizes our revenue in thousands by segment:
 
 
 
Three Months Ended March 31,
 
 
 
2019
 
 
2018
 
 
Percentage
Change (1)
 
 
 
(Restated)*
 
 
 
 
 
 
 
Direct selling
 $33,420 
 $35,311 
  (5.4)%
As a % of Revenue
  81.1%
  82.1%
  (1.0)%
Commercial coffee:
    
    
    
Processed green coffee
  100 
  4,985 
  (98.0)%
As a % of Segment Revenue
  1.3%
  64.9%
  (63.6)%
Milling and processing services
  4,826 
  - 
  N/A 
As a % of Segment Revenue
  62.6%
  -%
  N/A 
Roasted coffee and other
  2,779 
  2,698 
  3.0%
As a % of Segment Revenue
  36.1%
  35.1%
  1.0%
Total commercial coffee
  7,705 
  7,683 
  0.3%
As a % of Revenue
  18.7%
  17.9%
  0.8%
Commercial hemp
  67 
  - 
  N/A 
As a % of Revenue
  0.2%
  -%
  N/A 
Total Revenues
 $41,192 
 $42,994 
  (4.2)%
 
*
See Note 2 to the unaudited condensed consolidated financial statements.
(1)
Percentages denoted as N/A do not contain prior period comparatives
 
 
 
-47-
 
 
Cost of Revenues
 
For the three months ended March 31, 2019, overall cost of revenues decreased approximately 20.2% to $14,343,000 as compared to $17,982,000 for the three months ended March 31, 2018.
 
The direct selling segment cost of revenues increased 0.8% to $10,665,000 when compared to $10,576,000 for the same period last year, primarily due to product sales mix and an increase in stock and equity-based compensation expense of $74,000.
 
The commercial coffee segment cost of revenues decreased 50.9% to approximately $3,638,000 when compared to $7,406,000 for the same period last year. This was primarily attributable to the shift in revenue from processed green coffee sales to milling and processing services year on year. As revenue for milling services does not contain a cost of goods sold component, related to processed green coffee, this shift in revenues to milling and processing services lowers our cost of revenue. Cost of revenues from the sale of processed green coffee was $607,000 or 7.9% of commercial coffee segment revenues for the three months ended March 31, 2019. During the three months ended March 31, 2018, cost of revenues on processed green coffee sales were $4,809,000 or 96.5% of commercial coffee segment revenues. Cost of revenue for roasted coffee increased 16.7% to $3,031,000 for the three months ended March 31, 2019.
 
The commercial hemp segment cost of revenues was $40,000.
 
Cost of revenues includes the cost of inventory including green coffee, shipping and handling costs incurred in connection with shipments to customers, direct labor and benefits costs, royalties associated with certain products, transaction merchant fees and depreciation on certain assets.
 
Gross Profit
 
For the three months ended March 31, 2019, gross profit increased approximately 7.3% to $26,849,000 as compared to $25,012,000 for the three months ended March 31, 2018. Overall gross profit as a percentage of revenues increased to 65.2%, compared to 58.2% in the same period last year, primarily due to the increased revenues in the commercial coffee segment.
 
Gross profit in the direct selling segment decreased by 8.0% to $22,755,000 from $24,735,000 in the prior period primarily as a result of the decrease in revenues and the higher cost of sales discussed above. Gross profit as a percentage of revenues in the direct selling segment decreased by approximately 1.9% to 68.1% for the three months ended March 31, 2019, compared to 70.0% in the same period last year.
 
Gross profit in the commercial coffee segment increased to approximately $4,067,000 compared to $277,000 in the prior period. Gross profit as a percentage of revenues in the commercial coffee segment increased to 52.8% for the three months ended March 31, 2019, compared to 3.6% in the same period last year. The increase in gross profit in the commercial coffee segment was primarily due to the overall increase in the processing and milling of unprocessed green coffee at our mill that in turn drove higher gross profits from the combination of processed green coffee sales and revenues on milling and processing services during the three months ended March 31, 2019. Gross profit from the sales of processed green coffee was a negative $507,000 or 6.6% of commercial coffee segment revenues and gross profits from milling and processing services was $4,826,000.
 
Gross profit in the commercial hemp segment was $27,000 related to the acquisition of Khrysos which closed on February 15, 2019.
 
 
 
-48-
 
 
Below is a table of gross profit (loss) by segment (in thousands) and gross profit as a percentage of segment revenues:
 
 
 
Three Months Ended March 31,
 
 
 
2019
 
 
2018
 
 
Percentage
Change (1)
 
 
 
(Restated) (1)
 
 
 
 
 
 
 
Direct selling
 $22,755 
 $24,735 
  (8.0)%
  Gross Profit % of  Segment Revenues
  68.1%
  70.0%
  (1.9)%
Commercial Coffee:
    
    
    
Processed green coffee
  (507)
  176 
  (388.1)%
  Gross Profit % of Segment Revenues
  (6.6)%
  2.3%
  (8.9)%
Milling and processing services
  4,826 
  - 
  N/A 
  Gross Profit % of Segment Revenues
  62.6%
  -%
  N/A 
Roasted coffee and other
  (252)
  101 
  (349.5)%
  Gross Loss % of Segment Revenues
  (3.3)%
  1.3%
  (4.6)%
Total commercial coffee
  4,067 
  277 
  1,368.2%
  Gross Profit % of Segment Revenues
  52.8%
  3.6%
  49.2%
Commercial hemp
  27 
  - 
  N/A 
  Gross Profit % of Segment Revenues
  40.3%
  -%
  N/A 
Total
 $26,849 
 $25,012 
  7.3%
  Gross Profit % of Revenues
  65.2%
  58.2%
  7.0%
 
* See Note 2 to the unaudited condensed consolidated financial statements.
 
(1) Percentages denoted as N/A do not contain prior period comparatives
 
Operating Expenses
 
For the three months ended March 31, 2019, our operating expenses increased 55.2% to $38,790,000 as compared to $24,988,000 for the three months ended March 31, 2018. The increase included $12,892,000 in stock and equity-based compensation expense (see Note 11, to the condensed consolidated financial statements).
 
For the three months ended March 31, 2019, the distributor compensation paid to our independent distributors in the direct selling segment decreased 4.4% to $14,890,000 from $15,578,000 for the three months ended March 31, 2018. This decrease was primarily attributable to the decrease in revenues. Distributor compensation as a percentage of direct selling revenues increased to 44.6% for the three months ended March 31, 2019 as compared to 44.1% for the three months ended March 31, 2018.
 
For the three months ended March 31, 2019, total sales and marketing expense increased 14.9% to $4,019,000 from $3,499,000 for the three months ended March 31, 2018. This increase included an increase of $471,000 in equity-based compensation expense. Excluding the increase in equity-based compensation expense, the increase in sales and marketing expense would have been 1.4%.
 
  In the direct selling segment, sales and marketing expense increased by 12.8% to $3,715,000 in the current quarter from $3,292,000 for the same period last year. This increase included an increase of $471,000 in equity-based compensation expense. Excluding the increase in equity-based compensation expense, sales and marketing expense would have decreased by 1.5%. In the commercial coffee segment, sales and marketing costs increased by $84,000 to $291,000 in the current quarter compared to the same period last year, primarily due to increased advertising costs and compensation expense. Sales and marketing expense was $13,000 in the commercial hemp segment.
 
 
 
-49-
 
 
For the three months ended March 31, 2019, total general and administrative expense increased 236.3% to $19,881,000 from $5,911,000 for the three months ended March 31, 2018. This increase included an increase of $12,421,000 in equity-based compensation expense. Excluding the increase in equity-based compensation expense, the increase in general and administration expense would have been 27.2%.
 
  In the direct selling segment, general and administrative expense increased by 223.7% to $16,459,000 in the current quarter from $5,084,000 for the same period last year. This increase included an increase of $10,995,000 in equity-based compensation expense. Excluding the increase in equity-based compensation expense, general and administrative expense would have increased by 7.7%. This increase was primarily due to an increase in accounting and legal fees. In addition, there was no contingent liability revaluation adjustment in the current quarter compared to a reduction in expense of $213,000 for the same period last year. In the commercial coffee segment, general and administrative costs increased by $2,065,000 or 249.7% to $2,892,000 in the current quarter compared to $827,000 in the same period last year. This increase included an increase of $1,425,000 in equity-based compensation expense. Excluding the increase in stock based compensation expense, general and administration expense in the commercial coffee segment would have increased by 77.4%. This was primarily due to an increase in wages, incentives, warehouse storage costs, workers’ compensation costs and profit-sharing expense of $243,000, compared to a profit-sharing benefit of $223,000 in the same period last year. General and administrative expense was $530,000 in the commercial hemp segment, mostly related to wages, supplies and general office costs.
 
Operating Income (Loss)
 
For the three months ended March 31, 2019, the Company reported an operating loss of $11,941,000 as compared to an operating income of $24,000 for the three months ended March 31, 2018. This was primarily due to the increase of $12,966,000 in non-cash and equity-based compensation expense discussed above. Excluding the increase in equity-based compensation expense, the Company would have reported an operating income of $1,025,000 in the current quarter. 
 
Total Other Expense
 
For the three months ended March 31, 2019, total other expense decreased by $2,061,000 to $21,000 as compared to other expense of $2,082,000 for the three months ended March 31, 2018. Total other expense includes net interest expense, the change in the fair value of derivative liabilities and extinguishment loss on debt.
 
Net interest expense decreased by $205,000 for the three months ended March 31, 2019 to $1,507,000, compared to $1,712,000 for the three months ended March 31, 2018.
  
Change in fair value of derivative liabilities increased by $774,000 for the three months ended March 31, 2019 to $1,486,000 in other income compared to $712,000 for the three months ended March 31, 2018. Various factors are considered in the pricing models we use to value the warrants including our current stock price, the remaining life of the warrants, the volatility of our stock price, and the risk-free interest rate. Future changes in these factors may have a significant impact on the computed fair value of the Company’s derivative liabilities. As such, we expect future changes in the fair value of the warrants and may vary significantly from period to period (see Notes 8 & 9, to the condensed consolidated financial statements).
 
For the three months ended March 31, 2018, we recorded a non-cash extinguishment loss on debt of $1,082,000 as a result of the triggering of the automatic conversion of the 2017 Notes associated with our July 2017 Private Placement to common stock. This loss represented the difference between the carrying value of the 2017 Notes and embedded conversion feature and the fair value of the shares that were issued. The fair value of the shares issued were based on the stock price on the date of the conversion. There was no loss on debt extinguishment in the current quarter. (See Note 8, to the condensed consolidated financial statements).
 
 
 
-50-
 
 
Income Taxes 
 
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in income in the period that includes the effective date of the change. We have determined through consideration of all positive and negative evidences that the deferred tax assets are not more likely than not to be realized. A valuation allowance remains on the U.S., state and foreign tax attributes that are likely to expire before realization. We have approximately $146,000 in AMT refundable credits, and we expect that $73,000 will be refunded in 2019. As such, we do not have a valuation allowance relating to the refundable AMT credit carryforward. We have recognized an income tax expense of $298,000 which is our estimated federal, state and foreign income tax expense for the three months ended March 31, 2019. The difference between the effective tax rate and the federal statutory rate of 21% is due to the permanent differences, change in valuation allowance, state taxes (net of federal benefit), and foreign tax rate differential.
 
Net Loss
 
For the three months ended March 31, 2019, the Company reported a net loss of $12,260,000 as compared to net loss of $2,308,000 for the three months ended March 31, 2018. The primary reason for the increase in net loss when compared to the prior period was due to the increase in operating loss of $11,965,000, and increase in income taxes of $48,000, offset by the increase in other income of $2,061,000. The primary reason for the increase in operating loss was the increase of $12,966,000 in non-cash equity-based compensation expense.
 
Adjusted EBITDA
 
EBITDA (earnings before interest, income taxes, depreciation and amortization) as adjusted to remove the effect of equity-based compensation expense and the non-cash loss on extinguishment of debt and the change in the fair value of the derivatives or "Adjusted EBITDA," increased 58.4% to $2,407,000 for the three months ended March 31, 2019 compared to $1,520,000 in the same period for the prior year.
 
Management believes that Adjusted EBITDA, when viewed with our results under GAAP and the accompanying reconciliations, provides useful information about our period-over-period growth. Adjusted EBITDA is presented because management believes it provides additional information with respect to the performance of our fundamental business activities and is also frequently used by securities analysts, investors and other interested parties in the evaluation of comparable companies. We also rely on Adjusted EBITDA as a primary measure to review and assess the operating performance of our company and our management team.
 
Adjusted EBITDA is a non-GAAP financial measure. We calculate adjusted EBITDA by taking net income, and adding back the expenses related to interest, income taxes, depreciation, amortization, equity-based compensation expense and the change in the fair value of the warrant derivative, as each of those elements are calculated in accordance with GAAP.  Adjusted EBITDA should not be construed as a substitute for net income (loss) (as determined in accordance with GAAP) for the purpose of analyzing our operating performance or financial position, as Adjusted EBITDA is not defined by GAAP.
 
 
 
-51-
 
 
A reconciliation of our adjusted EBITDA to net loss for the three months ended March 31, 2019 and 2018 is included in the table below (in thousands):
 
 
 
Three Months Ended
March 31,
 
 
 
2019
 
 
2018
 
Net loss
 $(12,260)
 $(2,308)
Add/Subtract:
    
    
Interest, net
  1,507 
  1,712 
Income tax provision
  298 
  250 
Depreciation
  475 
  432 
Amortization
  670 
  827 
EBITDA
  (9,310)
  913 
Add/Subtract:
    
    
Equity-based compensation
  13,203 
  237 
Change in the fair value of derivatives
  (1,486)
  (712)
Extinguishment loss on debt
  - 
  1,082 
Adjusted EBITDA
 $2,407 
 $1,520 
 
Liquidity and Capital Resources
 
Sources of Liquidity  
 
At March 31, 2019 we had cash and cash equivalents of approximately $2,540,000 as compared to cash and cash equivalents of $2,879,000 as of December 31, 2018.
 
Cash Flows
 
Cash used in operating activities. Net cash used in operating activities for the three months ended March 31, 2019 was $4,831,000 as compared to net cash used in operating activities of $1,427,000 for the three months ended March 31, 2018. Net cash used in operating activities consisted of a net loss of $12,260,000 and $6,072,000 in changes in operating assets and liabilities, partially offset by net non-cash operating expenses of $13,501,000.
 
Net non-cash operating expenses included $1,145,000 in depreciation and amortization, $11,344,000 in stock-based compensation expense, $1,859,000 in equity issuance for services, $199,000 in amortization of debt discounts, $281,000 in stock issuance cost related to true-up shares and $159,000 in increase in inventory reserves, offset by $1,486,000 related to the change in fair value of warrant derivative liability.
 
Changes in operating assets and liabilities were attributable to decreases in working capital, primarily related to changes in accounts receivable of $3,369,000, inventory of $1,283,000, prepaid expenses and other current assets of $111,000, deferred revenues of $44,000 and accrued expenses and other liabilities of $2,713,000. Increases in working capital primarily related to changes in accounts payable of $54,000 and accrued distributor compensation of $854,000.
 
Cash used in investing activities. Net cash used in investing activities for the three months ended March 31, 2019 was $2,716,000 as compared to net cash used in investing activities of $156,000 for the three months ended March 31, 2018. Net cash used in investing activities consisted of $1,350,000 in payments made towards the construction of a large mill in Nicaragua, $500,000 in cash paid related to the acquisition of Khrysos, offset by cash acquired of $75,000 and other purchases of property and equipment.  
 
Cash provided by financing activities. Net cash provided by financing activities was $7,106,000 for the three months ended March 31, 2019 as compared to net cash provided by financing activities of $3,762,000 for the three months ended March 31, 2018.
 
Net cash provided by financing activities consisted of net proceeds of $6,023,000 from issuance of equity and convertible notes, $1,451,000 from the issuance of common stock from the at-the-market offering including exercise of stock options and warrants, net. Net proceeds from line of credit of $176,000, offset by $35,000 in payments to reduce notes payable, $128,000 in payments related to contingent acquisition debt, $368,000 in payments related to capital lease financing obligations and $11,000 in dividends paid.
 
 
 
-52-
 
 
Future Liquidity Needs
 
The accompanying condensed consolidated financial statements have been prepared and presented on a basis assuming we will continue as a going concern. We have sustained significant losses during the three months ended March 31, 2019 of $12,260,000 and $2,308,000 for the three months ended March 31, 2018. Net cash used in operating activities was $4,831,000 for the three months ended March 31, 2019 compared to net cash used in operating activities of $1,427,000 for the three months ended March 31, 2018. We do not currently believe that our existing cash resources are sufficient to meet our anticipated needs over the next twelve months from the date hereof. Based on our current cash levels and our current rate of cash requirements, we will need to raise additional capital and will need to further reduce our expenses from current levels. These factors raise substantial doubt about our ability to continue as a going concern.
 
During the quarter ended March 31, 2019, our operations did not generate sufficient cash to meet our operating needs and we supplemented the revenue generated from operations with cash proceeds of debt and equity offerings. We raised additional capital through equity and convertible notes offerings during the current quarter and we entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with The Benchmark Company, LLC (“Benchmark”), as sales agent, pursuant to which the Company may sell from time to time, at its option, shares of its common stock, par value $0.001 per share, through Benchmark, as sales agent (the “Sales Agent”), for the sale of up to $60,000,000 of shares of the Company’s common stock.
 
However, despite such actions, we do not believe that our existing cash resources are sufficient to meet our anticipated needs over the next twelve months from the date hereof. We are also considering additional alternatives, including, but not limited to equity financings and debt financings. Depending on market conditions, we cannot be sure that additional capital will be available when needed or that, if available, it will be obtained on terms favorable to us or to our stockholders.
  
We anticipate revenues to continue to grow and we intend to make necessary cost reductions and reduce non-essential expenses.
 
Failure to raise additional funds from the issuance of equity securities and failure to implement cost reductions could adversely affect our ability to operate as a going concern. There can be no assurance that any cost reductions, implemented will correct our going concern issue. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.
 
Off-Balance Sheet Arrangements
 
There were no off-balance sheet arrangements as of March 31, 2019.
 
Contractual Obligations
 
There were no material changes from those disclosed in our most recent annual report.
 
Critical Accounting Policies
 
The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited condensed consolidated financial statements and revenues and expenses during the periods reported. Actual results could differ from those estimates. Information with respect to our critical accounting policies which we believe could have the most significant effect on our reported results and require subjective or complex judgments by management is contained in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2018.
 
Recent Accounting Pronouncements
 
Recent accounting pronouncements are disclosed in Note 1 to the accompanying condensed consolidated financial statements of this Quarterly Report on Form 10-Q/A.   
 
 
-53-
 
 
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk
 
As a Smaller Reporting Company as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item 3 of Part I.
 
ITEM 4. Controls and Procedures
 
(a)   Evaluation of Disclosure Controls and Procedures
 
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of March 31, 2019, the end of the quarterly fiscal period covered by this quarterly report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that there was a material weakness in the Company’s internal control over financial reporting that was identified during the fourth quarter of 2018 and the first quarter of 2019 for the commercial coffee segment relating to not having proper processes and controls in place to require sufficient documentation of significant agreements and arrangements in accounting for significant transactions with respect to certain operations within our coffee segment.
 
Additionally, in conjunction with our 2019 annual audit, management concluded that there was a material weakness in the Company’s internal control over financial reporting that was identified during the first quarter of 2019 for the commercial hemp segment relating to not having proper processes and controls in place in regard to accounting for significant transactions related to acquisitions.
 
Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this report and upon that discovery, our Chief Executive Officer and Chief Financial Officer concluded that as of the end of the period covered by this report, although we have made improvements, our disclosure controls and procedures were still not effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.  
 
(b)   Changes in Internal Control Over Financial Reporting
 
Management’s Remediation Efforts
 
Commercial Coffee Segment
 
During our 2019 annual review of internal controls, we reviewed revenues related to our commercial coffee segment, specifically the 2019 green coffee sales program. We concluded that specific 2019 green coffee revenue recorded at gross should have been recorded at net which equates to processing revenue for milling “wet” green coffee and which reflects the value of the performance obligation to provide green coffee milling services. As a result, we did not have an adequate review process over revenue recognition which resulted in an error in our financial statements.
 
This represented a material weakness in our internal control over financial reporting. For the quarter ended March 31, 2019 we have restated our Unaudited Condensed Consolidated Balance Sheet, Unaudited Condensed Consolidated Statement of Operations, Unaudited Condensed Consolidated Statements of Stockholders’ Equity, and the Unaudited Condensed Consolidated Statement of Cash Flows.
 
The restatement corrected the error in the presentation of revenue activity related to the specific green coffee sales to properly reflect net revenue where applicable. To remediate the issue, we have an additional review process for oversight and review of the revenue recognition policy to ensure revenue transactions are appropriately recorded. We will continue to assess the effectiveness of its internal control over financial reporting and take steps to remediate any potentially material weaknesses expeditiously.
 
 
 
-54-
 
 
Commercial Hemp Segment
 
During our annual review of internal controls, we concluded that our recording of the acquisition of Khrysos Global, Inc., the commercial hemp segment, specifically the valuation of certain fixed assets and the valuation of stock issued as consideration related to the acquisition was not appropriately fair valued. As a result, we did not have an adequate review process or procedures over acquisitions resulting in a misstatement to our financial statements. This represented a material weakness in our internal control over financial reporting. For the quarter ended March 31, 2019 we have restated our Unaudited Condensed Consolidated Balance Sheet, the Unaudited Condensed Consolidated Statement of Stockholders’ Equity, and the Unaudited Condensed Consolidated Statement of Cash Flows.
 
The restatement corrected the error related to property and equipment, net, goodwill and shareholders’ equity. To remediate the issue, we have added an additional review process for oversight and review of the acquisition process to ensure acquisition transactions are appropriately recorded. We will continue to assess the effectiveness of its internal control over financial reporting and take steps to remediate any potentially material weaknesses expeditiously.
 
During 2020, management implemented a remediation plan that included updating our current policies and implementing procedures and controls over future acquisitions. Until the material weaknesses are remediated, and our associated disclosure controls and procedures improve, there is a risk that a material error could occur and not be detected. 
 
 
 
-55-
 
 
PART II. OTHER INFORMATION
 
ITEM 1. LEGAL PROCEEDINGS
 
We are from time to time, the subject of claims and suits arising out of matters related to our business. We are a party to litigation at the present time and may become party to litigation in the future. In general, litigation claims can be expensive, and time consuming to bring or defend against and could result in settlements or damages that could significantly affect financial results. It is not possible to predict the final resolution of the current litigation to which we are party to, and the impact of certain of these matters on our business, results of operations, and financial condition could be material. Regardless of the outcome, litigation has adversely impacted our business because of defense costs, diversion of management resources and other factors.
 
ITEM 1A. RISK FACTORS
 
Any investment in our common stock involves a high degree of risk. Investors should carefully consider the risks described in our Annual Report on Form 10-K as filed with the SEC on April 15, 2019, and all of the information contained in our public filings before deciding whether to purchase our common stock. The following information and updates should be read in conjunction with the information disclosed in Part 1, Item 1A, “Risk Factors,” contained in our Annual Report on Form 10-K as filed with the SEC on April 15, 2019. Except as set forth below, there have been no material revisions to the “Risk Factors” as set forth in our Annual Report on Form 10-K as filed with the SEC on April 15, 2019.
 
There is substantial risk about our ability to continue as a going concern, which may hinder our ability to obtain future financing.
 
The accompanying condensed consolidated financial statements as of March 31, 2019 have been prepared and presented on a basis assuming we will continue as a going concern. We have sustained significant losses during the three months ended March 31, 2019 of $12,260,000. Net cash used in operating activities was $4,831,000 for the three months ended March 31, 2019 compared to net cash used in operating activities of $1,427,000 for the three months ended March 31, 2018. We do not currently believe that its existing cash resources are sufficient to meet our anticipated needs over the next twelve months from the date hereof. Based on our current cash levels as of March 31, 2019, our current rate of cash requirements, we will need to raise additional capital and we will need to significantly reduce our expenses from current levels to be able to continue as a going concern. There can be no assurance that we can raise capital upon favorable terms, if at all, or that we can significantly reduce our expenses.
 
We have identified material weaknesses in our internal controls, and we cannot provide assurances that this weakness will be effectively remediated or that additional material weaknesses will not occur in the future. If our internal control over financial reporting or our disclosure controls and procedures are not effective, we may not be able to accurately report our financial results, prevent fraud, or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported financial information and may lead to a decline in our stock price.
 
Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. Due to errors in our financial statements for the three months ended March 31, 2019 we have restated our Unaudited Condensed Consolidated Balance Sheet, Unaudited Condensed Consolidated Statement of Operations, and the Unaudited Condensed Consolidated Statement of Cash Flows. We have commenced measures to remediate the identified material weaknesses in our internal controls: however, there can be no assurance that the weaknesses will be effectively remediated or that additional material weaknesses will not occur in the future.
 
 
 
-56-
 
 
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
All sales of our common stock that were not registered under the Securities Act have been previously disclosed in our filings with the Securities and Exchange Commission except for the sales of unregistered securities set forth below during the three months ended March 31, 2019;
 
On March 10, 2019, we closed our second tranches of its 2019 January Private Placement debt offering pursuant to which we entered into subscription agreements with thirteen (8) accredited investors that had a substantial pre-existing relationship with us pursuant to which we received aggregate gross proceeds of $540,000 from thirteen (8) accredited investors that had a substantial pre-existing relationship with us and we issued to such investors notes in the aggregate principal amount of $540,000 and an aggregate of 10,800 shares of common stock. The placement agent received 12,200 shares of common stock in aggregate for the first and second tranches. Each note matures 24 months after issuance, bears interest at a rate of six percent (6%) per annum. We issued the securities in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act. We relied on this exemption from registration for private placements based in part on the representations made the investors with respect to their status as accredited investors, as such term is defined in Rule 501(a) of the Securities Act.
 
On March 13, 2019, we determined that three of the investors of our August 2018 Private Placement became eligible to receive additional shares of our common stock as it was referred to in their respective Purchase Agreement as True-up Shares. Total number of additional shares issued to those three investors is 44,599 shares of restricted shares of our common stock. We issued the shares of our common stock in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act. We relied on this exemption from registration for private placements based in part on the representations made the investors when they engaged in the August 2018 Private Placement with respect to their status as accredited investors, as such term is defined in Rule 501(a) of the Securities Act.
  
On March 18, 2019, we entered into a two-year Secured Promissory Note with two (2) accredited investors that had a substantial pre-existing relationship with us pursuant to which we raised cash proceeds of $2,000,000 and issued 20,000 shares of our common stock par value $0.001 for each $1,000,000 invested as well as for each $1,000,000 invested five-year warrants to purchase 20,000 shares of our common stock at a price per share of $6.00. The notes pay interest at a rate of eight percent (8%) per annum and interest is paid quarterly in arrears with all principal and unpaid interest due at maturity on March 18, 2021. We issued the securities in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act. We relied on this exemption from registration for private placements based in part on the representations made the investors with respect to their status as accredited investors, as such term is defined in Rule 501(a) of the Securities Act.
 
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
 
None.
 
ITEM 4. MINE SAFETY DISCLOSURES
 
Not applicable.
 
ITEM 5. OTHER INFORMATION
 
None.
 
 
 
-57-
 
 
ITEM 6. EXHIBITS
 
The following exhibits are filed as part of this Report:
 
EXHIBIT INDEX
 
Exhibit No.
 
Exhibit
 
At the Market Offering Agreement dated January 7, 2019, by and between Youngevity International, Inc. and The Benchmark Company, LLC incorporated by reference to the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 7, 2019 (File No. 001-38116)
 
Form of Investor Warrant incorporated by reference to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2019 (File No. 001-38116)
 
Form of Contingent Warrant incorporated by reference to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2019 (File No. 001-38116)
 
Form of Contingent Warrant #2 incorporated by reference to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2019 (File No. 001-38116)
 
Form of 6% Convertible Notes incorporated by reference to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 15, 2019 (File No. 001-38116)
 
Second Amended and Restated 2012 Stock Option Plan incorporated by reference to the Definitive Information Statement on Schedule 14C filed with the Securities and Exchange Commission on January 16, 2019 (File No. 001-38116
 
Exclusive Agreement with Icelandic Water Holdings hf. dated January 10, 2019 incorporated by reference to the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 11, 2019(File No. 001-38116)
 
CLR Siles Mill Construction Agreement dated January 15, 2019 incorporated by reference to the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 15, 2019 (File No. 001-38116)
 
Securities Purchase Agreement dated February 6, 2019, with Daniel Mangless incorporated by reference to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2019 (File No. 001-38116)
 
Asset and Equity Purchase Agreement by and between Youngevity International, Inc., Khrysos Industries, Inc., Khrysos Global, Inc., INX Holdings, LLC, Leigh Dundore and Dwayne Dundore incorporated by reference to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2019 (File No. 001-38116)
 
Form of Subscription Agreement to purchase 6% Convertible Notes incorporated by reference to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 15, 2019 (File No. 001-38116)
 
Security Agreement between Youngevity International, Inc. and investors incorporated by reference to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 15, 2019 (File No. 001-38116)
31.1*
 
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*
 
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS
 
XBRL Instance Document
101.SCH
 
XBRL Taxonomy Extension Schema Document
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
*Filed herewith.
 
 
-58-
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
YOUNGEVITY INTERNATIONAL INC.
 
(Registrant)
 
 
Date: September 13, 2021
/s/ Stephan Wallach
 
Stephan Wallach
 
Chief Executive Officer
 
(Principal Executive Officer)
 
 
 
 
Date:  September 13, 2021
/s/ William Thompson
 
William Thompson
 
Chief Financial Officer
 
(Principal Financial Officer)
 
 
 
 
  
 
-59-
Youngevity (NASDAQ:YGYI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Youngevity Charts.
Youngevity (NASDAQ:YGYI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Youngevity Charts.